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ABSTRACT 
                                                                                                                                                                      
Oligodeoxynucleotides containing CpG motifs (CpG-ODN) have been shown to 
stimulate the innate immune system against a variety of bacterial, viral, and protozoan 
infections in a variety of vertebrate species. The objectives of this study were to 
investigate the immunostimulatory effect of CpG-ODN against Salmonella 
Typhimurium infection and the formulation and delivery of CpG-ODN by the in ovo 
route. Day-old broiler chicks or embryonated eggs (day 18th of incubation) received 
either 50 μg of CpG-ODN, 50 μg of non-CpG-ODN, or saline. At day four-post hatch, 
all birds were subcutaneously inoculated by Salmonella Typhimurium. Clinical signs, 
pathology, bacterial isolations from the air sacs, and mortality were observed for ten 
days following challenge. The survival rate of the birds that received CpG-ODN via in 
ovo or in vivo treatments was significantly higher than the control group. Salmonella 
Typhimurium level in the peripheral blood and pathology were significantly lower (p < 
0.001) in CpG-ODN group compared to the control group. In order to investigate the 
effect of formulation of CpG-ODN, embryonated eggs (day 18th of incubation) were 
inoculated with either 50 μg of CpG-ODN alone or CpG-ODN formulated with 
polyphosphazene, liposome, or Emulsigen®. Four days after administration of CpG-
ODN formulations, the birds were challenged with E. coli by subcutaneous injection. 
Clinical signs, pathology, bacterial isolations from the air sacs, and mortality were 
observed for seven days following challenge. The birds that received either CpG-ODN 
or CpG-ODN formulated with polyphosphazene had significantly higher survival rates 
(30 and 60%) compared to the birds in groups receiving either non-CpG-ODN or saline. 
 ii
Bacterial loads in the air sacs were lower in groups treated with formulated CpG-ODN 
compared to the CpG-ODN alone or control groups. However, formulation of CpG-
ODN with liposomes or Emulsigen® did not increase the immunoprotective effect 
against E. coli infection. We showed that treatment with CpG-ODN protects neonatal 
chickens against an intracellular bacterial infection and that co-treatment of CpG-ODN 
with polyphosphazene enhances the immunoprotective effect of CpG-ODN. 
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INTRODUCTION 
 
Many Salmonella serotypes can infect poultry. Some serotypes, such as 
Salmonella enterica subspecies enterica serotype Pullorum and Salmonella enterica 
subspecies enterica serotype Gallinarum, are host specific for chickens while other 
serotypes, such as Salmonella enterica subspecies enterica serotype Typhimurium, 
Salmonella enterica subspecies enterica serotype Enteritidis, and Salmonella enterica 
subspecies enterica serotype Heidelberg are able to infect a range of hosts (Gast 2003). 
Salmonella infections are responsible for many acute and chronic diseases in poultry, 
including fowl typhoid and pullorum disease (Gast 2003). In chickens, the cecum is the 
primary colonization site of Salmonella (Xu et al. 1988), although the cloaca (Xu et al. 
1988) and the crop (Impey and Mead 1989) are also commonly colonized. Cross 
contamination with Salmonella between birds can occur during transit to market. There 
is evidence that poultry products are one of the primary sources of Salmonella infection 
in humans (Hald et al. 2004), where it can cause severe disease. Contamination of 
poultry products with Salmonella is therefore a major public health problem, and results 
in substantial economic loss every year.  
Salmonella Typhimurium is a common cause of salmonellosis among humans 
and animals in many countries, including Canada (Leon-Velarde et al. 2004). 
Salmonella Typhimurium has been reported to be responsible for 40 to 70% of human 
salmonellosis cases (Khakhria et al. 1997; Leon-Velarde et al. 2004), and has been one 
of  the most common bacteria isolated from hatching eggs in Canada in recent decades 
(Poppe et al. 1998). Contamination of broiler chicks with Salmonella Typhimurium may  
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occur by vertical or horizontal transmissions (Gast 2003). In poultry rearing barns, a 
number of environmental factors can contribute to the contamination of naïve chicks, 
including air, litter, feed, unclean facilities, and vectors such as insects, humans, rodents 
and wild birds (Gast 2003). Multiple virulence factors in the genome of Salmonella 
Typhimurium facilitate efficient colonization, invasion of the gastrointestinal tract, and 
intracellular survival in the host (Libby 2004). The genomes of pathogenic Salmonella 
species (spp.) have large groups of preserved virulence genes that are not present in the 
similar region of nonpathogenic species. These regions of chromosomal DNA are 
referred to as Salmonella pathogenicity islands  ( SPIs) (Blum et al. 1994).  These SPIs 
include  SPI-1, which encodes a type three secretion system (T3SS) associated with 
invasion; SPI-2, which encodes a T3SS that contributes to intracellular survival; SPI-3, 
which encodes genes associated with intracellular proliferation; SPI-4, which encodes 
genes for toxin secretion and apoptosis; and SPI-5, which encodes a number of different 
T3SS-associated proteins (Libby 2004). Most Salmonella Typhimurium isolates also 
have virulence plasmids that encode genes required for causing systemic disease (Poppe 
et al. 1998). A Salmonella plasmid, which contains genes for fimbriae is important for 
replication in extraintestinal sites such as the liver and spleen (Ahmer et al. 1999). 
Salmonella Typhimurium induces high mortality in neonatal chickens, especially those 
under three days of age (Gast and Beard 1989). High mortality rates in neonatal 
chickens are due to an immature immune system that permits multiplication of bacteria 
in blood, and replication in the reticuloendothelial tissue of the liver and spleen (Gast 
and Beard 1989; Gast 2003). Birds inoculated with Salmonella at seven to ten days of 
age show lower mortality and  fewer  clinical signs, due to maturation of  gut  associated  
 
lymphoid tissues (GALT) (Gast and Beard 1989).  
Salmonella Typhimurium infection is difficult to control, as bacteria can be 
introduced to poultry farms from many sources (mentioned above). In order to control 
the disease, biosecurity practices must prevent the infection from all sources and must 
be verified by periodic testing (Gast 2003), which is costly for producers. Probiotic 
therapy can limit bacterial colonization of the intestinal tract by increasing levels of 
interferon (IFN)-  and interleukin (IL)-2, thereby activating innate immunity (Dalloul et 
al. 2004). Probiotic therapy of chicks increases the number of Ig-producing cells (IgM, 
IgG) detected in Peyer’s patches and cecal tonsils, and also increases the length of the 
cecal tonsils (Yurong et al. 2005). However, probiotics are only useful prior to 
infections, and therefore not useful for concurrent neonatal infections (Toro et al. 2005). 
Vaccinating breeders with live and killed vaccines may reduce the susceptibility of their 
progeny to Salmonella Typhimurium infection. Nevertheless, vaccines have not been 
effective in consistently preventing  infection (Gast 2003).  
It has been shown that Salmonella Typhimurium is capable of developing 
resistance to antibiotic therapy (Verma et al. 2004). The emergence of resistance in 
Salmonella has been associated with the use of antibiotic agents in livestock including 
chickens (Gray et al. 1996). Therefore, replacement of antibiotics with alternative 
measures to prevent salmonellosis should be a priority for poultry research.  
Over recent decades, many studies have been conducted to identify and 
understand biochemical events and signals   that stimulate immune responses to 
pathogens. In 1992, Yamamoto et al. first reported that bacterial DNA (bDNA) has 
immune stimulatory effects and can  activate  natural killer  (NK) cells, while  vertebrate  
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DNA (vDNA) has no such effect (Yamamoto et al. 1992). Later, Krieg et al. (1995) 
showed that bDNA has a specific molecular structure, cytosine phosphodiester guanine 
(CpG), in which the cytosine is unmethylated (Krieg et al. 1995) and is recognized as 
foreign by the host. Synthetic CpG-Oligodeoxynucleotides (ODN) mimic pathogen 
associated molecular patterns (PAMPs) (Krieg 2002). They are recognized by pathogen 
recognition receptors (PRRs) of the immune system (Krieg 2002). In mammals, CpG-
ODN can directly or indirectly activate immune cells such as B and T lymphocytes and 
plasmacytoid dendritic cells (pDCs). It can also induce a variety of proinflammatory and 
anti-inflammatory cytokines, chemokines, and antibodies such as IL-1, IL-6, IL-10, IL-
12, IL-18, tumor necrosis factor (TNF)-α, INF-γ, and IgG mediated by toll-like receptor 
(TLR)-9 (Krieg et al. 1995).  
The immunostimulatory effect of CpG-ODN against many different infections 
has been studied in a variety of species such as fish (Jorgensen et al. 2001) , mammals, 
including food animals such as pigs (Kamstrup et al. 2001), cattle (Zhang et al. 2001), 
and sheep (Mena et al. 2003). Previously a chicken model has been used to investigate 
the immunoprotective effect of CpG-ODN against E. coli, an extracellular bacterial 
infection that causes high mortality in neonatal chickens (Gomis et al. 2004). Further 
studies have shown that CpG-ODN stimulate the innate, and later the adaptive immune 
system of chickens against a pathogen by stimulating the degranulation and oxidative 
activities of heterophils, and upregulation of nitric oxide (NO) production (He et al. 
2005). Therefore, consideration of CpG-ODN as an alternative treatment for   other    
important    infections   in   poultry    such    as   salmonellosis caused by Salmonella 
Typhimurium.   
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An optimal dose of CpG-ODN is required for induction of immune responses  
(Mutwiri et al. 2004). CpG-ODN are rapidly cleared from circulation through absorption 
by serum proteins such a albumin, and degradation by serum nucleases (Mutwiri et al. 
2004). Therefore, in some cases, repeated administration of CpG-ODN is required 
(Molenkamp et al. 2007). Previously, it has been reported that adjuvants such as 
liposomes such as Poly[di (carboxylatophenoxphosphazene)] (PCPP) (Alcon et al. 2006; 
Jaafari et al. 2007  Payne et al. 1998; Mutwiri et al. 2007), , and oil-in-water emulsion 
(Emulsigen®) (Aucouturier et al. 2001) can stimulate immune cells of the host against 
pathogens. It has also been shown that the immunostimulatory effect of CpG-ODN can 
be enhanced by adding adjuvants such as Emulsigen®  (Ioannou et al. 2002) and 
liposomes (Alcon et al. 2005a; Alcon et al. 2005b). However, it is not known whether 
the CpG-ODN with PCPP will enhance the immunostimulatory effect of CpG-ODN in 
chickens. 
Objectives were: 
1. To develop an animal model of Salmonella Typhimurium in neonatal broiler 
chickens.  
2. To investigate the effect of CpG-ODN in the neonatal broiler model. 
a. To determine the duration of protection against Salmonella Typhimurium in 
neonatal broilers. 
b. To determine the effect of CpG-ODN on Salmonella Typhimurium 
septicemia. 
c. To determine the effect of  in ovo delivery of CpG-ODN against Salmonella 
Typhimurium infection. 
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3. To determine if the immunoprotective effect of CpG-ODN was enhanced by addition 
of  PCPP  or Emulsigen® using an E. coli septicemia model in neonatal chickens. 
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1.0. LITERATURE REVIEW 
   1.1. Salmonella nomenclature 
 Before 2005, the nomenclature of genus Salmonella had been in a state of 
confusion. Two systems were commonly used. The system that confirmed the Rule of 
the Bacteriologic Code was used by a minority of bacteriologists, while a second 
system, which was proposed in 1987 by Le Minor and Popoff, was accepted by a 
majority of bacteriologists, despite the fact it was not consistent with the rules (Euzéby 
1999).  
In the system outlined by the Rule of the Bacteriologic Code, Salmonella 
cholereasuis had been considered as the only species of genus Salmonella and 
categorized into seven different subspecies (subsps). Salmonella choleraesuis subsp. 
arizonae;  Salmonella choleraesuis subsp. bongori; Salmonella choleraesuis subsp. 
choleraesuis; Salmonella choleraesuis subsp. diarizonae; Salmonella choleraesuis 
subsp. houtenae; Salmonella choleraesuis subsp. indica; and Salmonella choleraesuis 
subsp. salamae, Salmonella enteritidis, Salmonella paratyphi, Salmonella typhi, and 
Salmonella typhimurium (Euzéby 1999).  
Le Minor and Popoff  recommended that Salmonella enterica (type strain LT2) 
be   considered  the  only  species  of  the  genus  Salmonella (Le Minor 1987). LeMinor  
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and Popoff proposed that the name Salmonella choleraesuis was a heterotypic  synonym  
of "Salmonella enterica", and that Salmonella enteritidis, Salmonella typhi and 
Salmonella typhimurium were heterotypic synonyms of "Salmonella enterica subsp. 
Enterica. Salmonella enterica subspecies, which were suggested by these authors, were: 
Salmonella enterica subsp. arizonae", “Salmonella enterica subsp. bongori",  
"Salmonella enterica subsp. enterica", "Salmonella enterica subsp. diarizonae",  
"Salmonella enterica subsp. houtenae", "Salmonella enterica subsp. indica",  
and "Salmonella enterica subsp. salamae"(Le Minor 1987). 
 In 1999, Euzéby requested that the Judicial Commission of the International 
Committee for Systematic of Prokaryotes alter the nomenclature of Salmonella to be 
based on the Le Minor and Popoff’s system (Euzéby 1999). In 2005, the Judicial 
Commission issued an Opinion (the Judicial Opinion 80) that stated Salmonella enterica 
was the species of the genus Salmonella and accepted the combinations proposed by 
LeMinor and Popoff (Truper 2005). The Judicial Commission also agreed that the 
names Salmonella choleraesuis, Salmonella enteritidis, Salmonella paratyphi, 
Salmonella typhi, and Salmonella typhimurium are not conserved specific epithetic in 
the names of bacteria. Salmonella nomenclature proposed by the Judicial Opinion 80 
that is relevant is as follows: 
Salmonella enterica subsp enterica serotype Enteritidis,  
Salmonella enterica subsp. enterica serotype Typhi,  
Salmonella enterica subsp. enterica serotype Typhimurium,  
Salmonella enterica subsp. enterica serotype Pullorum,  
and Salmonella enterica subsp. enterica serotype Gallinarum. 
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      1.1.1. Salmonellosis 
Salmonella are gram-negative, facultative, intracellular bacteria that are 
widespread in nature and have the ability to infect a variety of mammalian and avian 
hosts (Gast 2003). Most potentially pathogenic bacteria in the genus Salmonella of 
veterinary importance belong to species Salmonella enterica subspecies enterica (Carter 
1990). Two major forms of the disease caused by this subspecies are septicemia and 
acute, sub-acute or chronic enteritis. Animals with the septicemic form of the disease 
experience high mortality, while animals with chronic enteritis experience low mortality 
with mild diarrhea (Gast 2003).  
 
      1.1.2. Typhoid and paratyphoid salmonellosis in poultry  
More than 2,400 serotypes of Salmonella enterica subspecies enterica have been 
identified (Le Minor et al. 1982). Serotypes that infect poultry are grouped into two 
categories (Gast 2003). The first category contains the non-motile serotypes.  They 
include Salmonella Pullorum, which infects young chickens and turkeys up to two to 
three weeks of age and causes pullorum disease, and Salmonella Gallinarum, which 
affects mature birds and causes fowl typhoid disease (Gast 2003). These serotypes are 
host-specific for avian species and have caused significant economic losses in the 
commercial poultry industry over recent decades (Gast 2003). The second category 
contains the motile serotypes, or paratyphoid Salmonella (Carter 1990). They can cause 
food borne diseases in humans. The most commonly reported  serotypes belonging to 
paratyphoid Salmonella are Salmonella Enteritidis and Salmonella Typhimurium 
(Barrow 2000).    Paratyphoid    Salmonella   serotypes    are    of    most    concern    for  
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the poultry industry, as they can cause mortality in poultry and readily enter the food 
chain where they may cause human disease (Barrow 2000).  
 
     
      1.1.3. Salmonella Typhimurium in neonatal chickens 
Chickens of one to two days of age are highly susceptible to Salmonella 
infection (Libby 2004). In the septicemic form of the disease, Salmonella replicates in 
the reticuloendothelial tissues of the liver and spleen and disseminates to a variety of 
internal organs, resulting in high mortality and morbidity (Barrow 1987). When orally 
administered, Salmonella Typhimurium adheres to the ceca of two-day-old chickens, 
causing low mortality but high morbidity (Gast 2003). Birds that recover from infection 
become carriers of Salmonella and remain as the main source of infection for other 
birds. Carrier birds shed Salmonella in their feces (Gast 2003).  
 
         1.1.3.1. Sources, vectors, transmission and pathogenesis of Salmonella 
             Typhimurium     
Salmonella can be transmitted horizontally via environmental contamination, 
fomites, feed, rodents, insects, and wild birds (Gast 2003; Strother 2005). Salmonella 
can also be introduced to neonatal poultry by vertical transmission from their infected 
parents (Gordon and Tucker 1965). In addition, Salmonella Typhimurium inside or on 
the surface of eggs can spread through hatcheries via air, land on hatching cabinets, and 
subsequently inoculate other neonatal chickens (Bailey et al. 1994).  
  Pathogenesis of salmonellosis follows several steps, including adherence to 
intestinal epithelial cells, invasion, and intracellular survival. Salmonella serotypes have  
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numbers of short filamentous structures or fimbria for adherence to Peyer’s patches and 
intestinal villi (Libby 2004). Virulence factors encoded in SPI-1 (Blum et al. 1994), SPI-
4 (Ahmer et al. 1999), and Salmonella virulence plasmids (Gulig 1990) are thought to 
play a role in invasion. Virulence factors encoded in SPI-1 provide accumulation of 
fluid in the intestine (Blum et al. 1994). Salmonella Typhimurium that survive in the 
intestine move to macrophages in the lymph nodes and then move into the circulatory 
system via the thoracic duct (Libby 2004). SPI-2 (Hensel et al. 1995; Vazquez-Torres et 
al. 2000) and virulence factors encoded by SPI-3 (Blanc-Potard and Groisman 1997) are 
essential for intra-macrophage survival. Virulence factors encoded in SPI-2 interferes 
with movement of nicotinamide adenosine dinucleotide phosphate (NADH) oxidase to 
Salmonella thereby preventing phagocyte dependent oxidative killing. Therefore, SPI-2 
is required for systemic phase of infection (Fang and Vazquez-Torres 2002).    
 
 
         1.1.3.2. Clinical signs associated with Salmonella Typhimurium in neonatal 
                      chickens 
Infection of eggs with Salmonella Typhimurium can lead to high mortality in 
embryos and newly hatched birds without clinical signs (Nakamura et al. 1993). Typical 
signs of Salmonella Typhimurium infection in older chickens and poults are anorexia, 
closed eyes, drooping wings, ruffled feathers and emaciation (Barrow et al. 1987). 
Watery diarrhea leading to dehydration and pasting of the vent is often seen in neonatal 
chickens (Gast 2003). Blindness (Padron 1990) and lameness (Gast 2003) have been 
observed sporadically. 
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         1.1.3.3. Pathology associated with Salmonella Typhimurium in chickens 
On gross examination, spleens and livers are swollen, congested, and 
hemorrhagic with necrotic foci (Gast 2003). Enlarged and congested kidneys may also 
be seen (Hoop and Pospischil 1993). Fibrinopurulent perihepatitis, pericarditis, 
airsacculitis and polyserositis have commonly been associated with salmonellosis in 
neonatal poultry (Padron 1990; Hoop and Pospischil 1993). Unabsorbed or coagulated 
yolk and yolk sacculitis may also be seen (Padron 1990). On histological examination, 
bacterial colonies, infiltration of inflammatory cells (heterophils, lymphocytes, and 
macrophages) and cell debris is observed (Holt and Porter 1992; Porter and Holt 1993). 
 
 
         1.1.3.4. Immunity against Salmonella in chicken 
 Host defense against pathogens such as Salmonella is initiated by the innate 
immune system, which in turn directs the development of the acquired immune 
response. Polymorphonuclear (PMN) leukocytes are cellular components of innate 
response, with the primary cell type in poultry being the heterophil. Heterophils have 
been previously shown to be the primary responders to Salmonella infections in 
chickens (Kogut et al. 1994). The importance of the avian heterophil in innate immune 
responses to Salmonella infections has been highlighted by the description of the 
expression of Toll-like receptors (TLRs) by avian heterophils (Kogut et al. 2005a). 
Kogut  et al. showed that avian heterophils are able to express TLR 1, TLR 2, TLR 3, 
TLR 4, TLR 5, TLR 6, TLR 7, and TLR 10 (Kogut et al. 2005a), but not TLR 9 (He et 
al. 2006; Kogut  et  al. 2006) during Salmonella septicemia. Recently, bacterial flagellin 
has    been   described   as    a    potent    stimulator    of    avian    heterophils    as    well 
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(Genovese et al. 2007). Flagellin leads to cell signaling events through TLR 5 that 
induces a high level of peripheral blood heterophils and the accumulation of leukocytes 
at the site of infection (Genovese et al. 2007). 
Macrophages are central effectors of the innate immune defense against 
Salmonella. These cells are able to kill the pathogen by oxygen and nitrogen reactive 
activities (Alter-Koltunoff et al. 2007). In addition, macrophages induce macrophage 
inflammatory proteins (MIP) in the spleen and liver, followed by production of IFN-γ, 
accompanied by increased numbers of both CD4 (+) and CD8 (+) T cells (TCs) against 
Salmonella (Okamura et al. 2005). Proinflammatory cytokines, which are induced 
following Salmonella infection include, IL-1-β, IL-6, IL-8, and IL-18 (Kogut et al. 
2005b). 
Salmonella infection can produce strong antibody responses by increasing the  
levels  of  IgG,  IgA, and  IgM  in  serum, intestinal contents, and  bile of  infected  birds 
(Gast 2003). Unlike IgA, IgG is only present in systemic sites; therefore, greater 
induction of Salmonella-specific IgG by Salmonella Typhimurium can be a response to 
a higher level of systemic infection (Beal 2006).  
Cell-mediated immunity against Salmonella Typhimurium infection and a strong 
delayed hypersensivity reaction in chickens two and five weeks after inoculation have 
also been reported (Hassan et al. 1991).  
 
   1.2. Escherichia coli infection in poultry  
E. coli   belongs   to   the   family   Enterobacteriaceae  and  is  a  gram-negative,  
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rod-shape bacterium that grows rapidly in bacteriological media. Many strains of E. coli 
have peritrichous flagella and are motile (Gyles 2004). Unlike Salmonella, E. coli is an 
extracellular pathogen. 
E. coli infection (colibacillosis) in poultry is usually a secondary infection that 
causes localized or systemic disease when a host’s defenses have already been damaged 
by either a primary disease (Barnes 2003) or by poor management and biosecurity 
practices (Dho-Moulin and Fairbrother 1999). However, E. coli can cause a primary 
infection in very young poultry at or soon after hatching. Pathogenic E. coli are isolated 
from the intestinal tracts of neonatal chicks more often than from eggs, which suggests 
that E. coli is transmitted horizontally and can spread rapidly after hatching (Harry and 
Hemsley 1965). Most E. coli serotypes isolated from poultry are pathogenic only to 
avian species (Harry and Hemsley 1965). 
 
      1.2.1. Virulence factors of E. coli in chicken  
Avian pathogenic E. coli (APEC) are present in the normal intestinal microflora 
and the bird’s environment. Biochemical characteristics and drug sensitivity of 
pathogenic and nonpathogenic isolates of E. coli are similar (Cloud et al. 1985). There is 
no single virulence factor that can differentiate all pathogenic and nonpathogenic   
strains of E. coli (Barnes 2003). Factors that generally do not correlate with virulence 
are hemolysis, heat-stable toxin, metabolic activity, motility, R-plasmids, and phage 
resistance (Vidotto et al. 1990; Fantinatti et al. 1994). Aerobic production, the presence 
of fimbriae (type1-curli-p) and flagella, or capsule (K1), and serum resistance are among 
virulence factors that have been described so far for APEC (La Ragione and Woodward 
2002).  
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Aerobactin- The effects of low levels of free iron on the growth of APEC in 
chicken are well established (Payne 1988; Martinez et al. 1990). Payen and Martinez 
showed that the majority of E. coli from septicemic chickens had the aerobic iron 
hunting system. This aerobactin system allowed APEC to grow under iron-limiting 
conditions, and it strongly correlated with mortality in neonatal chickens (Dho and 
Lafont 1984; Payne 1988; Martinez et al. 1990). 
Type 1 fimbria- Type 1 fimbria are long and thread-like filaments (Krogfelt and 
Klemm 1988). The expression of type 1 fimbriae by E. coli is mainly observed in the 
trachea, lungs, and air sacs of the birds (Pourbakhsh et al. 1997a; Pourbakhsh et al. 
1997b). They are significantly associated with adhesion of APEC to epithelial cells, 
colonization, invasion, and persistence in chicken (La Ragione and Woodward 2002). 
These findings extended those of Malaviya et al. who suggested that type 1 fimbria 
could be mast cell activators, and that this activation would result in phagocytosis and 
total recall of neutrophils to the site of infection in mice (Malaviya et al. 1996). 
 Curli fimbriae- Curli fimbriae are thin, hair-like filaments, which are found in 
most E. coli isolates (Olsen et al. 1989). Herwald et al. (1998) suggested that 
hypotension and coagulopathies, which are seen in severe E. coli infections, are 
associated with the ability of curli fimbriae to interact with number of host proteins such 
as fibronectin and fibrinolytic proteins, and coagulation cascades. Fibronectin is known 
to interact with many extracellular substances such as collagen, fibrin and heparin and 
also with specific membrane receptors on responsive cells (Herwald et al. 1998). La 
Ragione et al. (2000) recently showed that curli fimbriae of E. coli are important in 
colonization, invasion, and persistence of APEC in chickens (La Ragione et al. 2000).  
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 P fimbriae- P fimbriae or F11 have been described in a minority of APEC 
(Pourbakhsh and Fairbrother 1994). However, receptors for p fimbriae are absent in the 
trachea and they do not mediate adhesion to avian respiratory tissues. Therefore, P 
fimbriae might be involved in presence and persistence of pathogenic microorganism, its 
toxins in the blood or septicemia (Pourbakhsh et al. 1997b).  
 Flagella- Flagella are fine hair-like filaments, which are found on the most 
motile APEC (La Ragione and Woodward 2002). Flagella support bacterial penetration 
of intestinal mucus by passing through the underlying epithelial cells. They are 
important in colonization, invasion and persistence of APEC in chickens (La Ragione et 
al. 2000). 
 K1 antigen- The most common K antigen is K1. The K1 capsule is composed of 
polysaccharide. It is anti-phagocytic, and is involved in extra-intestinal infections and 
serum resistance (La Ragione and Woodward 2002).  
Serum resistance- Cell surface structures such as capsule, LPS or outer 
membrane protein mediate resistance to killing by complement (the factor that causes 
immune cytolysis, the lysis of antibody coated cells) in serum (Ellis et al. 1988). It has 
been shown that serum resistance is associated with avian septicemic strains of E. coli, 
and complement resistance is highly correlated with lethality in the chicken and 
moderately associated with chicken embryo lethality (Nolan et al. 1992; Wooley et al. 
1992).  
      1.2.2. Pathogenesis of respiratory form of E. coli in chickens  
E. coli infections occur when skin or mucosal barriers of chickens are 
damaged(e.g. unhealed navel, wounds, disruption of normal flora, tracheitis) (Gyles 
2004). APEC  mucosal infection results in the septicemic form of  E. coli in chickens 
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with early changes characterized by airsacculitis (Dho-Moulin and Fairbrother 1999). 
APEC adhere to respiratory epithelial cells by F1 pili (Dho-Moulin and Fairbrother 
1999; (Arp 1980) and P pili (Dho-Moulin and Fairbrother 1999; Dozois et al. 2000), 
after which they enter the bloodstream via the lungs (Ackermann and Cheville 1991) 
and air sacs (Pourbakhsh et al. 1997a) to reach internal organs.  
 
      1.2.3. Sources, vectors, and transmission of E. coli in chickens  
Eggshell contamination with  pathogenic E. coli  is a common  source of 
infection and can result in high chick mortality (Giovanardi et al. 2005). Eggshell 
contamination may also result from ovarian infection or salpingitis (Barnes 2003). 
Poultry house dust may contain 1x105-1x106 E. coli/g that can survive and are 
considered as a source of infection for long periods, especially under dry conditions 
(Harry and Hemsley 1965).  
 
      1.2.4. E. coli infections in neonatal chickens 
Hens inoculated experimentally may shed E. coli in up to 26% of their eggs  and 
cause the death of embryos late in the incubation period (Siccardi 1975). The clinical 
signs associated with colibacillosis are nonspecific and vary with age and concurrent 
diseases. E. coli causes death in newly hatched birds at or shortly after hatching (within 
24 - 48 hours) due to septicemia (Pourbakhsh et al. 1997a). The common form of E. coli 
in neonatal chickens is yolk sacculitis and omphalitis (Pourbakhsh et al. 1997a). 
Panophthalmitis  is  an  uncommon  consequence of  E. coli  septicemia  and  is  usually  
unilateral (Gyles 2004). 
 
 18
      1.2.5. Pathology associated with E. coli infections 
Gross lesions are omphalitis, yolk sacculitis, fibrinopurulant airsacculitis, 
pericarditis  perihepatitis (Gyles 2004), and  peritonitis (Cheville and Arp 1978). Acute 
septicemia with splenomegaly, congested muscles, and multiple necrotic foci of the liver  
occurs occasionally (Gyles 2004). Microscopically, caseous exudates consisting of 
heterophils, bacterial colonies, giant cells and macrophages may be visible (Cheville and 
Arp 1978). In severe cases of omphalitis, necrosis of the body wall and underlying skin 
may be seen (Gyles 2004). Yolk sacculitis and enlargement of yolk sacs are associated 
with delayed absorption of the yolk sacs  (Gyles 2004). 
 
   1.3. Overview of the avian immune system 
 The overall organization and mechanisms of the avian immune system are 
similar to those in mammals. In poultry, immune cells are located in primary lymphoid 
organs such as the thymus and the bursa of Fabricius, or secondary lymphoid organs 
such as the spleen, bone marrow, gland of Harder (located ventral and posteriomedial to 
the eyeball), and conjunctival-associated, bronchial-associated, and gut-associated 
lymphoid tissues. Primary lymphoid organs are the site for differentiation and 
maturation of T and B lymphocytes, while secondary lymphoid organs are principal sites 
of antigen-induced immune response (Sharma 1991).  
The  first  line of  defense  against  pathogens  that  enter  the  body is  the  innate 
immune system. The innate immune system includes phagocytic cells such as 
heterophils and macrophages (Qureshi et al. 2000); a complement system that produces 
proteins,  which   bind  to  bacteria  in  order  to  kill  the  bacteria,  or  enhance  bacterial  
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phagocytosis   (Koppenheffer et al. 1998); and NK cells. Although NK cells are neither -
T nor B lymphoid cells, they are cytotoxic for virus-infected and tumor cells (Sharma 
1981).  
Pathogens that can pass through host’s physical barriers or innate immune 
defense mechanisms induce a specific immune response (adaptive immunity) (Sharma 
1991). Adaptive immunity is mediated by a variety of cells, the most important of which 
are T cell receptors  ( TCR), B cell receptors (BCR ), and macrophages (Schauenstein et 
al. 1988). T lymphocytes (TC) recognize foreign Ags after the antigens have been 
processed by antigen presenting cells (APCs) (Sharma 1991). B lymnphocytes (BC) are 
able to recognize foreign Ags via immunoglobulin (IgM, IgG, and IgA) that project 
from the cell surface (Parvari et al. 1988). 
TCs, BCs, macrophages, and dendritic cells (DC) all secrete cytokines (Sharma 
1991). Cytokines  produced  by  T helper cells (Th) can be separated into two functional  
types, Th 1  and Th 2 based cytokines (Sharma 1991). Cytokines secreted by Th 1 cells 
help the cell-mediated branch of immune responses, such as: IFN-γ, which activates 
macrophages (Golemboski et al. 1992); IL-2, which promotes proliferation of TCs, 
CTL, NK cells, and  BCs  (Lawson et al. 2000); and  TNF-α ,  IL-12, and Il-18. 
Cytokines produced  by Th 2 cells, such as IL-4, IL-5, promote BC activation and 
antibody production (Sharma 1991). 
 
   1.4. Cytosine-phosphodiester-Guanine Oligodeoxynucleotides (CpG-ODN) 
      1.4.1. Early applications of CpG-ODN 
More  than  a century has  passed  since William Coley  introduced the deliberate  
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use of bacterial extracts for successful treatment of cancer (Wiemann and Starnes 1994). 
Since then, extracts of the attenuated Mycobacterium  bacillus Calmette Guerin (BCG) 
have become standard therapy for human bladder cancer (Morales 1978). DNA of 
Mycobacterium bovis strain BCG, which is composed of 70.0% DNA, 28.0% RNA, 
1.3% protein, 0.20% glucose, and 0.1% lipid. The DNA of Mycobacterium bovis was 
found to be the component of BCG that activates NK cells and induces tumor regression 
(Tokunaga 1984). It was later confirmed that purified BCG DNA induces NK cell 
activity and the production of type 1 and type 2 interferon in vitro (Yamamoto et al. 
1988). Investigators cloned mycobacterial genes or synthesized oligodeoxynucleotides 
(ODN), and found that certain nucleic acid sequences (palindromes) in these ODN were 
responsible for immune stimulatory effects (Yamamoto et al. 1992). Methylation of the 
cytosine phosphodiester guanine (CpG) was reported to have no influence on the 
immune stimulatory activities of the DNA (Kuramoto et al. 1992). Messina et al. (1991) 
reported that purified bDNA induced murine BC proliferation and immunoglobulin 
secretion, but that vDNA did not.  In contrast, they suggested that methylation of CpGs 
disrupted the unique higher ordered structure of bDNA molecules.  
 
      1.4.2. The location of CpG motifs  
Today,  most  of  the information  regarding CpG-ODN is based on studies using 
human  cells  and  mice. A long  history of human therapy with  CpG-ODN  encouraged 
further explorations of CpG-ODN using the human cell model. All information 
presented in this chapter is based on the studies using these two species as model.   
After  synthesizing  and  testing  several  hundred  ODNs, it became clear that an  
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adequate sequence element for inducing BC activation was a CpG dinucleotide in a 
particular base context (Krieg 2002). It is interesting that an increase in  the number of 
stimulatory CpG motifs in ODN increases the activity of the ODN, although the addition 
of a CpG into the terminal end of an ODN may actually reduce the degree of the BC 
activation (Krieg et al. 1995). Stimulatory activities of CpG were lost when CpG 
dinucleotides from ODN were eliminated (Krieg et al. 1995). 
 
      1.4.3. Immune recognition of CpG motifs as a defense mechanism 
The CpG content of vDNA and bacterial or viral DNA varies markedly (Krieg 
2002). The frequency of CpG dinucleotides in vertebrate genomes is only 25% of the 
predicted frequency for it to occur (Bird 1993). The most common base that precedes a 
CpG in vDNA is a cytosine (C) and the most common base that follows a CpG is a 
guanine (G) (Han et al. 1994). In addition to differences in CpG content between vDNA 
and bDNA or viral DNA, 70% of CpG dinucleotides in vertebrates are methylated at 
five positions, while fewer CpG dinucleotides are methylated in bacterial or viral DNA 
(Bird 1993).  Krieg et al. (2002) showed that the immune system recognizes CpG motifs 
using protective pathways that are also activated by (PRRs).  
TLRs are among  PRRs  that  mediate host recognition  of PAMPs  in  pathogens 
(Janeway and Medzhitov 2002). TLRs trigger an innate immune response that promotes 
the removal  of  foreign  pathogens and supports the  development of adaptive immunity 
(Akira et al. 2001). The effects of CpG-ODN on human and mouse cells have been well 
studied. CpG motifs must interact with independent receptor molecules (TLR9) 
presented  in endosomal  vesicles (Ishii et al. 2002)  before  triggering an innate immune  
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response (Katso et al. 2001). This interaction leads to the swelling and acidification of 
endocytic vesicles and generation of reactive oxygen species (Takeshita et al. 2001). 
BCs and plasmacytoid DCs (pDC) are the main cell types that express TLR9 and 
respond directly to stimulation by CpG-ODN (Takeshita et al. 2001; Gursel et al. 2002). 
Activation of these cells by CpG-ODN initiates an immunostimulatory cascade that 
induces maturation, differentiation and proliferation of NK cells, TCs and 
monocytes/macrophages (Klinman et al. 1996; Sun et al. 1998). Together these cells 
secrete cytokines and chemokines that create a proinflammatory (IL-1, IL-6, IL-18, and 
TNF) and Th 1-baised (interferon-γ, IFN-γ, and IL-12) immune environment (Ballas et 
al. 1996; Klinman et al. 1996). DNA with methylated CpG motifs (vDNA) does not 
result in cytokine/chemokine secretion (Klinman et al. 1996; Gursel et al. 2002). 
 
      1.4.5. Effect of the ODN backbone On CpG-mediated immune activity 
 Zhao  et al. (1993) used fluorescein-conjugated oligonucleotides to study the 
effects of phosphorothioate (PS) or phosphodiester (PO) backbone on surface binding, 
uptake, and degradation of mouse spleen cells (Zhao et al. 1993). They showed that 
binding and   uptake of BCs was higher in PS than in PO.  Phosphorothioate  completely  
blocked  PO binding because of its higher affinity for oligonucleotide binding sites on 
the cell membrane (Zhao et al. 1993). The level of CpG-induced BC activation was 200 
times greater  with  the PS  backbone than with  the PO backbone (Krieg 2002). On  the  
other hand, PS was less susceptible to DNase than PO (Stein et al. 1988). Stability 
against serum degradation can be noticeably enhanced by adding a PS backbone, which 
maintains  an  increased  immunostimulatory  effect  of  CpG-ODN (Ballas  et al. 1996).  
 
 Oligodeoxynucleotides with normal PO backbone degrades within four hours 
especially in lymphocytes. This significantly reduces its ability to cause BC proliferation 
(Krieg 2001). Overall, ODN with a double-stranded palindrome are likely more stable 
against serum degradation than ODN without a duplex (Ballas et al. 1996).    
Ballas  et al. found that in mice, all of the ODN lytic activity is held in the NK 
cells, which are a valuable cell immune population against pathogens (Ballas et al. 
1996). Including a PS backbone in ODN may reduce stimulation of macrophage and NK 
cell activity against pathogens. This reduction and decreased immune response may be 
due to less binding of PS backbone ODN to the macrophage receptors compared with an 
ODN in which at least part of the backbone is PO (Ballas et al. 1996). However, the 
effect of PS on NK cells can be increased by adding poly G sequences at the 5’ and 3’ 
ends of the ODN (Ballas et al. 1996). The effects of different ODN backbones on CpG-
mediated immune activities are summarized in Table 1.1. 
 
Table 1.1. Comparison of PS and PO backbone on CpG-mediated immune activities  
  
  Immunomodulatory                                  PS                                        PO 
  activity 
 
  Binding and uptake 
  of BCs                                                        +++                                         + 
 
  Susceptibility to DNase                               +                                          +++ 
 
  NK cell activity                                          +++                                         + 
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 1.4.6. Identifying distinct classes of immune stimulatory CpG-ODN 
         1.4.6.1. Characteristics of class A CpG-ODN (CpG-A ODN) (Krug et al. 2001a) 
Oligodeoxynucleotides that contain PO backbones are particularly effective at 
activating NK cells and inducing IFN-α production from pDCs, and are accordingly 
known as CpG-A ODN (Vallin et al. 1999) (Krieg 2001). CpG-A ODN contain poly-G 
motifs with PS connections at the 5’ and 3’ ends and a PO at the ODN center and single 
CpG motif. These properties induce the highest degree of NK cell activation and IFN-α 
production in virus-free four- to six-week-old mice (Ballas et al. 1996).  Krug  et  al. 
(2001) showed that CpG-A ODN directly induce the secretion of IFN-α from  pDCs, 
which indirectly support the subsequent maturation of  antigen presenting cells (APCs)  
using human cell model. 
However, immunostimulatory effects of CpG-A ODN with no poly-G motifs can 
be enhanced by administering cationic lipids (CLs) intravenously to mice (Mui et al. 
2001), or by administering antibodies collected from patients with systemic lupus 
erythematosus (Vallin et al. 1999). Plasma concentrations of IL-12, IFN-γ, IL-6, 
monocyte chemoattractant protein-1 and TNF-α was higher when CpG-ODN plus CLs 
was given intravenously to mice than when the same dose of free CpG-ODN was given. 
CpG-A ODN and bDNA had similar effects on activation of NK cells, but CpG-A ODN 
had a stronger effect on induction of IFN-α production and a lower effect on activation 
of BCs than bDNA (Krieg 2002). The immunostimulatory effects of CpG-A ODN are 
shown in Table 1.2. 
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         1.4.6.2. Characteristics of class B CpG-ODN (CpG-B ODN)  
CpG-B  ODN  encode  multiple  CpG  motifs  on  a  PS   backbone,  trigger  the 
differentiation of APCs and induce the proliferation and activation of BCs (Krug et al. 
2001a) (Hartmann and Krieg 2000). CpG-B ODN enhance BC stimulatory properties, 
such as secretion of IL-6 and IL-10, but reduce NK cell stimulation (Krieg 2001). They 
also produce TNF-α and  IgM  (Klinman 2004). CpG-B ODN  have no  poly-G  motifs  
(Krieg 2001).  In addition to secreting cytokines and  immunoglobulin,  BCs activated 
by CpG-B ODN express increased levels of molecules such as class two major 
histocompatibility complex (II MHC), cluster of differentiation (CD) 80 and CD 86 
(Krieg et al. 1995; Davis et al. 1998). The immune stimulatory effects of CpG-B ODN 
are shown in Table 1.2. 
 
         1.4.6.3. Characteristics of class C CpG-ODN (CpG-C ODN) 
 CpG-C ODN are composed entirely of PS backbones (Klinman 2004). They can 
contain a TCGTCG sequence at the 5’ end, and internally a GTCGTT sequence         
(Hartmann et al. 2003). This class of ODN contains multiple CpG motifs and is able to 
stimulate    BCs    to   secrete   IL-6   and   IgM,    and    stimulate    pDCs    to    produce 
IFN-α, thereby combining stimulatory properties of both CpG-A ODN and CpG-B ODN 
classes (Hartmann et al. 2003). The immune stimulatory effects of CpG-C ODN are 
shown in Table 1.2. 
 
         1.4.6.4. Characteristics of CpG-S ODN  
This class of ODN blocks TLR 9, TLR 7 and / or TLR 8 and RNA-mediated  
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Table 1.2. Characteristics of immune stimulatory effects of different classes of 
                  CpG-ODN 
 
ODN Type Structure characteristics Immune activity 
 
 
CpG-A ODN 
 
-Contain poly-G motifs 
  and single CpG motif (CG) 
-Mixed PS and PO backbone 
 
1-Activation of NK cells 
2-Induction of IFN-α 
    from pDC   
3-APC maturation,  
    mediated by IFN-α 
 
CpG-B ODN 
-Contain no poly-G motifs 
  and multiple CpG motifs 
-PS backbone 
1-Proliferation and 
   activation of BCs 
2-Secretion of IL-6, IL- 
   10, TNF, IgM  
3-Increase level of 
    II MHC, CD 80, and 
    CD 86 
 
CpG-C ODN 
-Contain multiple CpG motifs 
-PS backbone 
1-Stimulation of BCs 
    to secret IL-6 
2-Stimulation of DCs to 
    produce IFN-α 
 
CpG-S ODN 
-Contain CCT motifs near the 
  5’ end, and at least one G-rich 
  area near the 3’ end 
1-Blocks TLR 9- TLR 7 
    and/or TLR 8, and  
    RNA-mediated  
    immune activation 
 
 
immune activation (Barrat et al. 2005). However, CpG-S ODN do not block activation 
of  immune  cells  through  TLR 4,  CD 40  or  the  BCR  (Lenert  et al.  2001). To be  
most effective at   blocking   CpG-induced   TLR 9   activation,  this  class  should  
contain  a CCT motif near the 5’ end, and at least one G-rich area near the 3’ end with 
three to five bases (Lenert et al. 2003). The immune stimulatory effects of CpG-S ODN 
are shown in Table 1.2. 
 
      1.4.7. Mechanism of actions of CpG-ODN  
CpG-ODN bind to cell membranes, likely due to strong bonds between G motifs 
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in the ODN and lipid bi-layers of the cell membrane (Hughes et al. 1994; Kimura et al. 
1994;  Krieg 2002). It is not clear whether cells take up CpG-ODN  through  a cell  
surface receptor or an intracellular signaling  pathway (Manzel and Macfarlane 1999). 
BCs and monocytic cells have the highest rates of CpG-ODN uptake, while TCs and 
neutrophils have a lower rate of uptake. Following uptake into lymphocytes, ODN move 
to the endosomal compartment where CpG-ODN send primary signals to stimulate 
immune system (Zhao et al. 1994). Endocytosis and endosomal acidification/maturation 
are both required for CpG-ODN to stimulate production of TNF-α.  
CpG-ODN are among the PAMPs that are recognized by TLR 9 (Krieg 2002). 
Among different CpG-ODN classes, CpG-B ODN are the only class that have been 
shown to directly activate human BCs and pDCs via TLR 9 (Bauer et al. 2001). The 
preferred CpG motif in humans is CTCGTT, and in mice is CACGTT (Bauer et al. 
2001). It is not clear if TLR 9 is present  in  endosomes, but  evidence  suggests  that  
TLR 9  expression  improves the endosomal uptake of CpG-ODN (Takeshita et al. 
2001). CpG-ODN activates BCs following activation of mitogen-activated protein 
kinase (MAPKs) within seven minutes, which in turn contributes to IL-12 production 
(Yi and Krieg 1998a). On the other hand, CpG-ODN triggers the activation of nuclear 
factor kappa B (NFκB) in human BCs and murine macrophages, which induces the 
production of reactive oxygen species (ROS) within five minutes as well as the 
protection of BCs against apoptosis (Yi et al. 1996; Sparwasser et al. 1997; Yi and 
Krieg 1998b; Hartmann and Krieg 2000). Activated NFκB also trigger multiple 
transcription factors, which are important regulators for proinflammatory cytokines 
(Sweet et al. 1998). 
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     1.4.8. Cellular responses to CpG-ODN  
 In general, CpG-ODN stimulates different immune cells, regardless of whether 
the DNA is in the form of genomic bDNA or in the form of synthetic ODN with a 
nuclease-resistant PS backbone. Different cellular responses to CpG-ODN are described 
in the next sections. The effects of CpG-ODN on different immune cells are shown in 
Fig. 1.1. 
 
         1.4.8.1. B cells (BCs)(Davis et al. 1998) 
In 1998, Jakob et al. showed that both bDNA and CpG-ODN stimulated BCs 
enter the G1 phase of the cell cycle and secrete proinflammatory cytokine (IL-6) and 
anti-inflammatory cytokine (IL-10) within a few hours (Jakob et al. 1998). The BC 
proliferation activity of CpG-ODN seemed to be a signal–dependent process, as it could 
greatly be enhanced if the BCR was engaged at the same time (Krieg et al. 1995; Tasker 
and Marshall-Clarke 2003).  
Low concentrations of CpG-ODN in mature peripheral BCs can be strongly  
synergistic with signals through BCRs, which results in a ten fold increase in BC 
proliferation, antigen-specific immunoglobulin secretion, and IL-6 secretion  (Krieg et 
al. 1995). Further studies showed that the CpG-induced IL-6 expression was required 
for BCs to subsequently secrete IgM (Yi et al. 1998). Davis et al. (1998) found that IgM 
levels in mice immunized with hepatitis B virus (HBV) surface  antigen  and CpG-ODN 
were five times higher than IgM levels in mice immunized with Ag and a standard 
adjuvant such as alum.  
Mice that did not produce IFN-γ induced less than half of the normal IL-6 and 
IgM response to CpG–ODN (Yi et al. 1996). However, in vivo administration of  CpG- 
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ODN stimulated NK cells to secrete IFN-γ, which enhanced BC responses in these mice 
(Cowdery et al. 1996; Yi et al. 1996). Yi et al. (1999) showed that CpG-ODN had anti-
apoptosis activity and could prevent the normal spontaneous apoptosis of isolated 
mature murine primary BCs.  
 
         1.4.8.2. Dendritic Cells (DCs) 
TLRs allow DCs to induce different patterns of immune responses in humans 
and mice depending on the pathogen (Krieg 2002). Among human DCs, only pDCs have 
been directly activated by CpG-ODN, through TLR 9 (Krieg 2002). CpG-ODN induces 
activation of plasmacytoid DCs which, increases the surface expression of II  MHC and 
the co-stimulation of molecules CD 86 and CD 40, secretes cytokines (IL-12, IL-18, 
TNF-α),  INF-α (through type 2 DC precursors) and chemokine (IL-8), and activates 
TCs (Hartmann and Krieg 1999; Kadowaki et al. 2001a; Kadowaki et al. 2001b; Krug et 
al. 2001a). Plasmacytoid DCs are also known for their role as the primary source of the   
IFN-α (Krieg 2002). Human monocyte-derived DCs do not express TLR 9, but do 
express IL-12 and IL-18 mRNA, which means that responses to CpG-ODN in humans 
are due to indirect effects (Krieg 2002). Like human pDCs, murine   bone   marrow-
derived  DCs   and   Langerhans cells can be activated by CpG-ODN. This activation 
occurs through maturation of immature  DCs  and  activation  of  mature  DCs  to  trigger 
APCs  rich in  II  MHC  and  to produce  high  levels of cytokines  such  as IL-12,  IL-6, 
and  TNF-α (Jakob et al. 1998;  Sparwasser et al. 1998;  Ban et al. 2000).  CpG-ODN  
induce  murine  monocyte- derived DCs  to produce IL-12 and  IL-18, but do not have 
any effect in upregulating co- stimulatory molecules (Krieg 2000). 
 
CpG-ODN
 MonocytesMacrophages
NK cellsPlasmacytoid 
DC
        B cells 
Increased production 
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Fig. 1.1. The effects of CpG-ODN on different immune cells  
     
         1.4.8.3. Monocytes and macrophages 
Kadowaki et al. (2001b) showed that while plasmacytoid pre-DC strongly 
expressed TLR 7 and 9, monocytes preferentially expressed TLR 1, 2, 4, 5, and 8. 
However, treatment  of  human  PBMC  with  CpG-ODN  stimulated  the  monocytes to  
express increased levels of CD 40 are found on matures B-lymphocytes and activates 
BCs. In addition, the treatment caused monocytes to produce IL-6 and TNF-α with 
delayed kinetics when compared to LPS (Hartmann and Krieg 1999). Among monocyte-
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related cells, murine macroglial cells and astrocytes were also activated by CpG-ODN 
(Deng et al. 2001; Schluesener et al. 2001). 
Murine macrophages/monocytes do not respond directly to CpG-ODN, as their 
activation requires a primary cytokine expression that includes IFN-γ (Sparwasser et al. 
1998). This means that the production of nitric oxide (NO), expression of the inducible 
nitric oxide synthase (iNOS) gene, and TNF-α release from macrophages and bone 
marrow-derived macrophages in response to bDNA are absolutely dependent on IFN-γ 
activities (Sweet et al. 1998).  
Chu  et al.  (1999)  demonstrated  that  treatment  of murine  macrophages for 18  
hours with CpG-ODN decreased surface expression of II MHC (no APC expression). 
However, these inhibitory effects of CpG-ODN on Ag processing did not occur after 
short treatments (e.g., two hours) with CpG-ODN. Moreover, CpG-ODN treatment did 
not change the endocytotic activity of macrophages (Chu et al. 1999).  
 
         1.4.8.4. Natural killer cells (NK cells)  
Many studies have confirmed that  NK cells  are  activated by  bDNA in murine, 
human, and other species (Kuramoto et al. 1992; Tokunaga et al. 1992; Yamamoto et al. 
1992). These studies have shown that the effects of CpG-ODN on murine NK cells are 
not direct and require either IFNs type 1 or the CpG-ODN-induced IFN-α induction in 
APCs,   which influence  the  expression of  IFN-γ  (Ballas  et al. 1996;  Cowdery  et al.  
1996). Therefore, CpG-ODN act as a co-stimulatory signal for murine NK cells (Ballas 
et al. 1996). In contrast, CpG-OPDN with CG palindromes and ACCGGT sequences 
can stimulate human NK cells directly (Ballas et al. 1996).  
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         1.4.8.5. T cells (TCs) 
In general, CpG-ODN are not known to stimulate TCs directly (Sun et al. 1998). 
This is not surprising, as TCs do not express TLR 9 (Sun et al. 1998). In the human 
immune system, pDCs and BCs express TLR 9 and thus are sensitive to CpG-ODN. In 
contrast, monocytes, myeloid DCs, and TCs, are activated indirectly by stimulated pDCs 
and BCs (Krug et al. 2001b; Hornung et al. 2002). However, CpG-ODN can stimulate 
murine APCs, and they produce IFN-α and activate IFN type 1 receptors and TCs (Sun 
et al. 1998).  
 
         1.4.8.6. Neutrophils 
In humans, CpG-ODN did not activate neutrophils against Mycobacterium 
tuberculosis (Neufert et al. 2001). However, CpG-ODN indirectly activated murine 
neutrophils (Krieg 2002). A large dose of CpG-ODN administered to mice increased the 
immune system’s ability to resist acute polymicrobial sepsis (Weighardt et al. 2000). 
While CpG-ODN did not change systemic levels of IL-12, IL-18 and IL-10 in mice, 
administration of CpG-ODN strongly enhanced accumulation of neutrophils at the 
primary site of infection. This was likely due to upregulation of phagocytic receptors 
and increased phagocytic activity (Weighardt et al. 2000). Thus, even though CpG-ODN 
do not appear to activate neutrophils directly, they do increase the effectiveness of 
neutrophils (Krieg 2002). 
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      1.4.9. Therapeutic application of CpG-ODN 
         1.4.9.1. Activation of innate immune defense against infection 
In the case of an infection, the host’s immune system can be activated when a 
specific molecular structure in a pathogen, known as PAMP, is recognized by PRRs 
(TLR 9) (Krieg 2002). Krieg et al.  (1998) showed that CpG-ODN might be such a 
molecular structure, and could be recognized by PRRs as well. They administered CpG-
ODN two days prior to Listeria monocytogenes challenge, and found that it could fully 
protect mice against infection. Protection was induced by increasing serum IL-12 and 
IFN-γ, and by activating DCs. The protective effect of CpG-ODN in this experiment 
lasted for at least two weeks. A number of studies have provided further evidence that 
CpG-ODN, given orally or by injection, can protect  many species against a wide  range  
of protozoan, bacterial, and viral pathogens (Krieg et al. 1998).  
Recently, in vivo studies showed that CpG-ODN can protect chickens against the 
intracellular bacterial infection Salmonella Enteritidis (He et al. 2005b) Protection 
against Salmonella Enteritidis was due to enhanced secretion of IL-6, IL-1β, IFN-γ; and 
NO production (He et al. 2005b). Oxidative burst activity in chicken monocytes and 
heterophils also played a role in the chickens’ immune system against bacteria (He et al. 
2007). Later, Gomis et al. (2004) showed that in ovo delivery of CpG-ODN could 
protect neonatal chickens against E. coli septicemia (Gomis et al. 2004).  
The     effect    of    CpG-ODN     against    viral    infections     such    as     HBV 
has been studied in the mice genetically deficient in type 1 IFN receptors. Therefore, the 
hepatocytes of these mice could not express TLR 9 (Olbrich et al. 2002). The antiviral 
effect of  CpG-ODN  in  this  model was likely due to secretion of IFN-α  in  response to  
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stimulation by CpG-ODN and activation of TLR 9.  
In addition to providing protection against infections, CpG-ODN has an effect on 
hematopoietic function of mice as well (Krieg 2002). Treatment of mice with high doses 
of PS CpG-ODN induced massive splenomegaly and increased spleen granulocyte-
macrophage colony forming units and early erythroid progenitors (burst-forming units-
erythroid) (Sparwasser et al. 1999).   
In conclusion, CpG-ODN can be recognized by TLR 9 and stimulate innate 
immune system of the host by activation of BCs and  DCs. Activation of these cells 
increase the production of IgM and cytokines, and increase APC function, which 
subsequently activate adaptive immune system by activation of T and NK cells,  and 
production of IFN-γ. The immunostimulatory effect of CpG-ODN has been shown 
against different viral, bacterial, and protozoan diseases in different species. 
 
1.4.9.2. Role of CpG-ODN as a vaccine adjuvant and in DNA vaccines  
Adjuvant activity of CpG-ODN in DNA vaccines have been studied by many 
researches. Mechanisms that induce adjuvant activities of CpG-ODN are:  
I- Synergy between TLR 9 and BCRs followed by stimulation of antigen-specific 
BCs (Krieg et al. 1995);   
II- Inhibition of BC apoptosis (Yi  et al. 1998);   
III- Enhanced  DCs maturation and differentiation, resulting in enhanced 
activation of Th 1 cells and strong cytotoxic T lymphocyte (CTL) generation (Lipford et 
al. 2000; Sparwasser et al. 2000). CpG-A ODN compared to CpG-B ODN may give 
weaker antibody, but stronger CTL response (Krieg 2002).  
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Recently, Ioannou et al. (2003) studied the safety of CpG-ODN as a vaccine 
adjuvant. They showed that subcutaneous injection of CpG-ODN induced less 
perivascular and necro-dermatitis reactions at the site of injection than did other 
adjuvants. Other adjuvants used in the study included Freund’s complete adjuvant 
(FCA), alum, Emulsigen®, and VTA. Systemic administration of CpG-ODN also did 
not cause significant inflammatory responses (Ioannou et al. 2003). 
Vaccines containing CpG-ODN can be administered via different parental and 
mucosal routes. CpG-ODN are an effective mucosal vaccine adjuvant as they induce 
both local and systemic humoral and cellular immune responses (Gallichan et al. 2001). 
For example, intranasal immunization of mice with influenza vaccines containing CpG-
ODN enhanced the production of influenza specific antibodies in mice (Moldoveanu et 
al. 1998). Intravaginal immunization of mice with herpes simplex virus type 2 plus 
CpG-ODN could induce specific immunity and protection against herpes (Kwant and 
Rosenthal 2004). Conjunctival, oral, and even transcutaneous vaccination with DNA 
vaccines could enhance protection against herpes simplex virus type 1 (Nesburn et al. 
2005), rotavirus (Dong et al. 2005) and Chlamydia muridarum in mice (Berry et al. 
2004).  
The adjuvant effects of CpG-ODN were improved markedly by ensuring that the 
ODN remained close to the Ag (Davis et al. 1998; Gursel et al. 2001). Researches 
showed that specific IgG responses could be increased by 10-100 folds by cross-linking 
the ODN and Ag with alum, lipid emulsions or vesicles (Davis  et al. 1998;  Klinman  et  
al. 1999a; Gursel et al. 2001). Recently, Jaafari  et al. (2007) found that encapsulation of 
CpG-ODN in liposomes improved the immunogenicity of Leishmania Ag. This 
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improved-immunogenicity effect is responsible for lower spleen parasite burden and 
higher IgG and IFN-γ production. 
Overall, using CpG-ODN as vaccine adjuvant leads to a decrease in the amount 
of Ag needed (Tighe et al. 2000). 
 
         1.4.9.3. Other immunotherapeutic activities of CpG-ODN  
 Anti-tumor effects- Anti-tumor effects of CpG-ODN have been recognized for 
decades. The immune cascade that is obtained by CpG-ODN results in the activation of 
NK cells and CLTs that assists the treatment of cancer (Klinman 2004).  
 Anti-allergic effect- Allergic diseases such as asthma which is an inflammatory 
disease of the airways, result from Th 2 type immune responses against environmental 
Ags (Barnes 2001). When CpG-ODN is combined with an allergen, the ODN stimulate 
an antigen-specific Th 1-cell response that prevent the development of Th 2-cell 
mediated allergic asthma (Klinman 2004). 
 
   1.5. Mechanism by which CpG-ODN act on the avian immune system  
Little is known   about  the   effects  of   CpG-ODN  on  immune  responses  in 
chickens. Investigations of the effectiveness of CpG-ODN in chickens can be divided 
into two types:   
I- Mechanism of CpG-ODN as adjuvant and   
II- Activities of CpG-ODN as stand alone immune stimulant. 
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      1.5.1. Mechanism of CpG-ODN as an adjuvant on the avian immune system 
         1.5.1.1. Studies without a pathogen challenge 
 These in vivo studies evaluated antibody response to a protein Ag such as bovine 
serum albumin (BSA) with CpG-ODN as an adjuvant. In order to investigate whether 
the immunostimulatory actions of CpG-ODN occur in avian species as in mammals, 15-
day-old chickens were orally immunized with BSA alone or BSA with CpG-ODN and 
the serum antibody response was followed (Vleugels et al. 2002). Vleugels et al. (2002) 
observed significantly higher and more persistent BSA-specific responses in the CpG-
treated group. These results suggested that CpG-ODN were very promising adjuvant in 
chickens and opened further investigations.  
Later, Ameiss et al. (2006) showed that a single dose of CpG-ODN administered 
early in neonatal life could significantly enhance antigen-specific humoral responses to 
BSA delivered orally to the chicken. This oral administration of CpG-ODN specifically 
enhanced both the IgM and IgA responses in the serum, distal ileum and cecum. These 
results suggested that oral administration of CpG-ODN might be very attractive for 
generating protection against enteric pathogens in commercial poultry (Ameiss et al. 
2006).  
Recently,  the  ability  of  IFA  in  combination  with  CpG-ODN  to  enhance the 
immunostimulatory effect of CpG-ODN was studied as well. This combination could 
maximize the production of IgY (specific antibody in the egg yolks) of laying hens 
against the fimbrial adhesion F 4 of porcine enterotoxigenic E. coli. In addition, CpG-
ODN were suggested to be safe in commercial conditions for the immunization of laying 
hens on a larger scale without  any adverse effect on the health of the birds or on the egg  
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yield for at least one year. (Levesque et al. 2007).  
 
         1.5.1.2. Studies with a pathogen challenge  
Previously, Vleugels  et al.  (2002)  proved  that  CpG-ODN  could  be  valuable 
adjuvant for poultry vaccines. Many studies have been conducted using CpG-ODN as 
vaccine adjuvant against some of the poultry viral and bacterial disease. Wang et al. 
(2003b) found that chicken immunized with an infectious bursal disease virus (IBDV) -
DNA vaccine had higher antibody titers than chickens immunized with the regular 
IBDV vaccine. Later, chickens were successfully immunized against IBD in Pakistan 
using the IBDV-DNA vaccine (Mahmood et al. 2006). The immunoadjuvant effects of 
CpG-ODN to other viral vaccines such as, Newcastle disease (ND) vaccine and its 
protective effects against ND virus in chicken were recently investigated as well 
(Linghua et al. 2007). The results demonstrated that the titer of serum IgG to ND 
vaccine and the proliferation of lymphocytes, and therefore the level of protection 
against ND were significantly stronger in chickens that received CpG-ODN than in the 
birds that received only ND vaccine.  
Recent results stimulated research into the effectiveness of CpG-ODN as an 
adjuvant to vaccines against some important poultry bacterial diseases, such as E. coli 
(Gomis et al. 2007) and Chlamydophila psittaci (Loots et al. 2006). Birds that received 
E. coli bacterin formulated with CpG-ODN had higher survival rates, lower numbers of 
E. coli isolation from internal organs, and higher IgG levels in comparison with the birds 
that received vaccines alone (Gomis et al. 2007). However, Chlamydophila psittaci-
CpG-ODN  combined  vaccine  in vivo  created  no  beneficial  effect  on  the  protective 
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     immune response of the birds against chlamydiosis (Loots et al. 2006)  
 
 
 
      1.5.2. Activities of CpG-ODN as a stand alone immune stimulant of the avian  
                immune system  
         1.5.2.1. In vitro studies 
 Studies have been conducted in vitro to investigate the mechanism by which 
CpG-ODN act at the cellular level in chicken. He et al.  (2003) used an avian 
macrophage cell line (HD11) and peripheral blood mononuclear cells (PBMCs) to 
evaluate the ability of CpG-ODN to stimulate NO, IL-1β, and IFN-γ production. These 
researches showed that stimulation of HD11 cells with 10 μm phosphodiester CpG-
ODN for 24 hours stimulated the production of NO (He et al. 2003). Maximum 
production of NO was seen when the cell line was stimulated with CpG-ODN 
containing GTCGTT, and enhancement of stimulatory effect was observed following 
increase the number of GTCGTT. Optimal NO stimulatory CpG-ODN also strongly 
stimulated the IL-1β gene expression in the macrophage HD11 cells and the  IFN-γ gene 
expression in PBMCs (He et al. 2003). 
Later, it was shown that the CpG-ODN that induced NO production 
characteristically required a clathrin-dependent endocytosis following endosomal 
maturations (clathrin is a protein that coats vesicles formed during endocytosis of 
materials on the surface of cells) (He and Kogut 2003).  
The first study on serum-dependent activation of leukocytes by CpG-ODN in 
chickens was done by He et al. (He et al. 2005a). CpG-ODN were found to be an 
immune  stimulant  of   chicken   heterophils.  Recognition  of   CpG-ODN  by   chicken  
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heterophils led to the release of granules. This serum-dependent heterophil 
degranulation was a phenomenon specific to CpG-ODN, as other microbial agonists 
such as LPS, lipoteichoic acid (found in the walls of most gram-positive bacteria), 
phorbol esters (activators of protein kinase C), and formalin-killed Salmonella 
Enteritidis did not induce heterophil degranulation (He et al. 2005a).  
Further studies were performed to investigate the in vitro stimulation of 
leukocytes by CpG-ODN in neonatal chickens (He et al. 2005b). These studies found 
that when ODNs stimulated heterophils or monocytes, the oxidative burst that generates 
ROS (an innate immune response of immune cells) increased (He et al. 2005b). The 
inflammatory immune response of chicken monocytes in response to CpG-ODN was 
also found to be enhanced by combining of bDNA and double-stranded RNA (He et al. 
2007). (He et al. 2007) 
         1.5.2.2. In vivo / In ovo studies 
    The immunoprotective effect of CpG-ODN has been investigated using in vivo 
studies against pathogens. The immunoprotective effect of CpG-ODN was first observed 
in broiler chickens using an  E. coli septicemia model (Gomis et al. 2003). Treating 
birds with a minimum of 10 μg of CpG-ODN at day 22 of age was protective against an 
E. coli septicemia infection (at day 25 of age). Chicken treated with CpG-ODN had 
reduced number of bacterial colonies isolated from peripheral blood, increased survival 
rates, and protection against E. coli infection for nearly six days (Gomis et al. 2003). 
Later, it was shown that CpG-ODN had protection against E. coli infection of not only 
mature, but also neonatal broiler chickens (Gomis et al. 2004). Neonatal chickens 
treated  with  50 μg  of  CpG  at  two days of age, and challenged three days later with E.  
 41
coli, were significantly protected from infection and had a higher survival rate than the 
control group. These results stimulated research into the immunostimulatory effect of 
CpG-ODN against other bacterial infections in chickens.  
He et al.  showed that 25 or 50 μg of CpG-ODN injected (intraperitoneal) to 
two-day-old birds had significantly lower level of organ invasion (the liver and spleen) 
by  Salmonella Enteritidis (inoculated the birds 24 hours post CpG-ODN treatment) 
compared with the control group (He et al. 2005b). The effect of CpG-ODN on the level 
of peritoneal Salmonella Enteritidis infection in neonatal chickens has also been 
investigated. Significant reduction of mortality was observed in chickens treated with 25 
or 50 μg of CpG-ODN injected intraperitoneally at day two of age. These birds were 
challenged with Salmonella Enteritidis four hours post treatment with CpG-ODN by 
intraperitoneal injection. The protective effects of CpG-ODN were demonstrated 
throughout the seven-day-period of experiment (He et al. 2005b). 
 Recently, the modern broiler industry adapted to in ovo vaccination for control of 
diseases such as Marek’s disease. This method reduces the costs of poultry production 
by injecting compounds in precisely calibrated volumes to large numbers of eggs per 
day, without causing trauma to developing embryos (Krieg 1999). The benefits of this 
method encouraged research into the potential of in ovo delivery CpG-ODN for 
enhancing immune protection of neonatal chickens against infections during the first 
week of life (Gomis et al. 2004). Gomis et al. (2004) showed that 50 μg of CpG-ODN 
injected into the chicken eggs at day 18 of incubation was protective against E. coli 
(inoculated the birds at three days of age).  
 The immunostimulatory  effect of CpG-ODN against protozoan diseases has also 
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been studied. In 2004, Dalloul et al. (2004) showed that CpG-ODN could be used as 
immunoprotective agents against the protozoan infection Eimeria in chickens, resulting 
in increased protection. Both intravenous and subcutaneous injections of 10 and 50 µg 
of CpG-ODN reduced the number of oocysts shed in birds, while oral delivery did not. 
Recent work has also showed that adding a PS backbone to CpG-ODN increases 
resistance to Eimeria infection in birds injected in ovo (Dalloul et al. 2004). (Wang et al. 
2003b) 
      1.5.3. Chicken TLRs  
 Many studies have demonstrated that chicken cells respond to pathogens with the 
same activities  known  for  mammalian  TLRs.  As in  mammals,  TLRs  are  PRRs of 
chickens and are able to recognize a specific molecular structure in foreign infectious 
microorganisms. These molecular structures are known as PAMPs and serve as a link 
between innate and adaptive immunity (Krieg 2002). CpG-ODN are among PAMPs that 
are recognized by TLRs (Krieg 2002). In mammals, intracellular localization of TLR 9 
suggests CpG-ODN must be recognized by this receptor in order to activate cellular 
function, as mice genetically deficient in this molecule show no CpG-ODN–induced 
activation of BCs, DC, or NK cells (Hemmi et al. 2000). It was previously described 
that CpG-ODN act at the cellular level and have strong immunoprotective effect against 
many bacterial infection in chicken. However, there is no evidence suggesting the 
existence of TLR 9 in chicken in recent studies. The question is, which avian TLR acts 
as a link between CpG-ODN and cellular signaling pathway to boost immune system 
against infection? Eight TLRs have been well described. TLRs 1, 2, 3, 4, 5, 6, 7 and 10 
(Boyd  et al. 2001;  Fukui et al. 2001;  Leveque et al. 2003;  Iqbal et al. 2005;  Philbin et 
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 al. 2005; He et al. 2006; Kogut et al. 2006). The TLR 4 of chickens is involved in 
resistance to Salmonella infection (Leveque et al. 2003), while the TLR 5 controls the 
entry of flagellated Salmonella into systemic sites (Iqbal et al. 2005). Recently, a new 
chicken TLR (TLR 21) was identified by Roach et al. (2005). This TLR shares the same 
biology with the fish TLR 21-TLR 23 family (Roach et al. 2005). TLR 8 has also been 
described in just  galliform bird  species such as  turkeys,  grouse,  chickens,  quails, and 
pheasants (Philbin et al. 2005).  
Information from the human and mouse TLR pathways allowed Lynn et al. 
(2003) to begin to reconstruct the TLR pathway in chicken (Lynn et al. 2003). These 
researches could detect a non-mammalian TLR (TLR 15). TLR 15 seemed to be specific 
to avian species as it differs from TLRs known in other vertebrates, and might respond 
to pathogens whose the host is the chickens. Later, Higgs et al.  (2006) conducted an in 
vitro-in vivo experiment using five-week-old Salmonella Typhimurium challenge model 
to locate this receptor (Higgs et al. 2006). TLR 15 was detected in the chicken embryo 
fibroblast cells of the spleen, bursa, bone marrow, and cecum of healthy chickens and 
over expressed during Salmonella Typhimurium infection in the cecum (Higgs et al. 
2006). Further studies are required to point out the possibility of recognition of CpG-
ODN by chicken TLR 15 during infection. 
 
 
   1.6. Adjuvants  
Adjuvants are  formulated  compounds or  additives  that,  when  combined  with 
Ags, help to direct or boost the body’s immune system (Gupta 1998). Adjuvants are 
classified in two broad categories: I- delivery systems that include particulate adjuvants 
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such as liposomes and emulsions (Singh and O'Hagan 2002),  and II- 
immunostimulatory adjuvants such as CpG-ODN (Davis et al. 1998). The ability of an 
adjuvant to qualitatively affect the outcome of the immune response is an important 
consideration, because of the need for vaccines against infections (Pashine et al. 2005). 
Adjuvants increase immunogenicity of weak Ags, modulate antibody isotypes, and 
enhance the speed and duration of immune responses (O'Hagan et al. 2001).  
Adjuvants activate  the  release  of  ILs  by  macrophages  and  some of them are 
administered by creating a depot at the site of injection to prolong the release and 
interaction of Ags with APCs. (Gregoriadis 1990). 
 
 
      1.6.1. Liposomes 
Liposomes are the smallest artificial vesicles that can be produced from natural 
non-toxic phospholipids and cholesterol (Jaafari et al. 2007). Liposomes are attractive 
candidates for the delivery of Ags due to their non-toxic nature, biodegradability, 
biocompatibility, adjuvanticity, and induction of cellular immunity. Early studies have 
shown that liposomes are good adjuvants due to their ability to induce cell-mediated 
immunity (CMI) (Manesis et al. 1979), to increase internalization of Ags by 
macrophages, to increase Ag presented to TCs, and to induce IgG subclasses (Davis et 
al. 1987).  
Recent  studies  suggest  that  the  adjuvant  effect  of  liposomes  is  due to depot 
formation at the site of injection, selective uptake of liposomal Ags into the regional 
lymph nodes and more efficient Ag presentation. Efficiency of Ag presentation 
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increases due to Ag clustering and massive delivery to APCs (Gregoriadis 1990; Jaafari 
et al. 2007).  
CLs potentiate a noticeable activation of innate immunity by the TLR 9 
stimulants, bDNA, and CpG–ODN (Ishii et al. 1997; Gursel et al. 2001; Sellins et al. 
2005). The ability of CL to potentiate activation of innate immunity by DNA is due to 
protection of DNA from extracellular degradation and enhanced entry of DNA into the 
endosomal compartment, where TLR 9 is selectively expressed (Briane et al. 2002; 
Rocha et al. 2002). The ability of CLs to promote entry into the cell via the endosomal 
compartment may also be important in activation by TLR 3. This is because TLR 3 is 
also expressed primarily in the endosomal compartment (Iwasaki and Medzhitov 2004).  
Liposomes have also been used to generate CD 8+ TC responses by introducing 
protein Ags into the cytosol and stimulating the I MHC pathway (O'Hagan and Valiante 
2003).  Verma et al. (2002) showed that when CpG-ODN are encapsulated in liposomes, 
their incorporation into DCs are increased and IL-12 enhanced. Moreover, NK cells are 
activated and IFN-γ is produced. Liposomal adjuvants used in this study are vaccine 
targeting adjuvant (VTA) and cationic lipid (CL).  
 
         1.6.1.1. Vaccine Targeting Adjuvant (VTA)  
Biphasic lipid vesicles  are liposomal  adjuvant and  formulations suitable for the 
delivery  of  proteins,  peptides,  and  oligo/polynucleotides  (Alcon et al. 2005a).  These 
vesicles are made up of:   
I- An outer membrane composed of two layers of vesicle-forming lipids   
II- A core compartment containing an oil-in-water emulsion and   
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III- A dose  of  an  immunogen  effective to elicit  an immune response (Foldvari 
1998).   
These formulations, known as VTAs, are designed for vaccine application and have 
been shown to enhance the adjuvant activity of CpG-ODN (Babiuk et al. 2004). Babiuk 
et al. (2004) showed that mice injected subcutaneously with CpG-ODN formulated in 
VTA had significantly higher serum IgG levels than mice injected with CpG-ODN 
alone. Additionally, mice given CpG-ODN formulated in VTA by intrperitonial 
injection had increased serum levels of IL-12 compared to the mice that received CpG-
ODN alone (Babiuk et al. 2004). Moreover, mice injected intravenously with CpG-ODN 
formulated in VTA had higher serum levels of IL-6, and IFN-γ than the mice that 
received CpG-ODN  alone (Mui et al. 2001). This  formulation  protected  mice  from  a 
lethal  herpes  simplex  virus  type  1  challenge  with  minimal  clinical  signs  using a 
scratch model (Irie et al. 1993; Babiuk et al. 2004). Systemic administration of CpG-
ODN encapsulated in VTA protected pigs against porcine pleuropneumonia infection 
(Alcon et al. 2003). Protection of pigs was attributed to an increased immune response 
induced by the outer membrane lipoprotein A of Actinobacillus pleuropneuminiae 
(Alcon et al. 2003). 
 
         1.6.1.2. Cationic Lipid (CL)  
CL is another  liposomal  adjuvant  that  was studied  in  this  thesis. A  number  
of studies have investigated the effects of CL and CL formulated with CpG-ODN on the 
immune system. CLs were capable of binding strongly to vaccine Ags against influenza 
and induced robust anti-influenza immune responses both after subcutaneous and 
intranasal administration in mice (Guy et al. 2001). Both routes activated innate immune 
responses such  as  induction of  proinflammatory  cytokines and immune cell activation  
(Guy et al. 2001). D'Souza  et al.  (2002) also showed that CL increased the level of IgG 
by three to ten-fold in immunized mice with tuberculosis vaccines that included CL. CL 
also increased production of splenic TC-derived Th 1-type cytokines such as IL-2 and 
IFN-γ (D'Souza et al. 2002).  
Encapsulation of CpG-ODN in a CL increased Ag-specific IFN-  production, 
and IFN- -dependent IgG2a production by 10-40 fold in mice (Gursel et al. 2001). 
These increases are consistent with the preferential induction of a Th 1-based immune 
response compared to CpG-ODN alone (Gursel et al. 2001). Recently, it has been shown 
that this formulation enhanced DNA binding and up taking in murine DCs, and also 
induced proinflammatory cytokine secretion (Yoshinaga et al. 2007). Cytokines 
included TNF-α and IL-12 secreted from granulocyte–macrophage colony–stimulating 
factor (GM-CSF)-cultured bone marrow-derived DCs (Yoshinaga et al. 2007). Mice 
injected intrarectally or intranasally with CpG-ODN formulated with CL generated 
higher levels of IgG and IgA antibodies than did mice injected with CpG-ODN 
intramuscularly (Joseph et al. 2006). Increased antibody levels occurred both in mucosal 
(Peyer's patches, lamina propria, colon) and peripheral (spleen, serum) sites of the 
intrarectally and intranasally immunized mice (Joseph et al. 2006).  
Intravenous administration of CL is likely to cause more severe side effects than 
intrapulmonary administration, and can be lethal at higher doses of the complex (Yew 
and Scheule 2005). 
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      1.6.2. Polyphosphazenes  
Polyphosphazenes are potent immunostimulant  adjuvants with a high molecular 
weight. They contain a long-chain backbone of phosphorus and nitrogen atoms with 
organic side groups attached to each phosphorus (Payne and Andrianov 1998). 
Combining this phosphorus-nitrogen backbone with appropriate side groups leads to 
almost unlimited possibilities for preparing materials (Allcock 1990). The ability of 
hydrophobic polymer matrices to degrade slowly in aqueous solutions is one of the most 
critical properties in determining the potential of these materials as controlled release 
systems (Langer 1990).  
One of the most important potential applications of polyphosphazenes relates to 
their activity as immunoadjuvant compounds that enhance the immune response (Payne 
et al. 1998; Andrianov et al. 2004). Lu et al. (1996) showed that polyphosphazenes are 
effective adjuvants in a vaccine against human immunodeficiency virus type 1 (HIV-1) 
in intramuscularly and intranasally immunized rhesus monkeys, rabbits, and mice. 
Therefore, polyphosphazenes have the potential to become important adjuvants to 
vaccine candidates in human clinical trials.   
The effects of CpG-ODN formulated with polyphosphazene against influenza 
infection in mice have been studied recently (Mutwiri et al. 2007). Results indicated that 
higher levels of Th 1, Th 2 type cytokines, and IgG1, IgG2 were associated with 
production of both IFN-γ and IL-4 in mice immunized with CpG-ODN plus 
polyphosphazenes compared to mice immunized with CpG-ODN alone (Mutwiri et al. 
2007).   
The biological  performance  of  polyphosphazenes  depends  on  their molecular  
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weight and composition. It is therefore of critical importance to consider the properties 
of    these    polymers   when   using    them   as   adjuvants   (Payne   et al.   1998).   The 
polyphosphazene adjuvants used in this study are Poly [di (carboxylatophenoxy 
phosphazene)] (PCPP) and Poly [di (sodium carboxylatoethylphenoxy) phosphazene] 
(PCEP). 
 
         1.6.2.1. Poly [di (carboxylatophenoxy phosphazene)] (PCPP)   
PCPP is a water-soluble phosphazene polyelectrolyte. PCPP is of considerable 
interest because of their unique physicochemical and biological properties and their 
important applications as materials for microencapsulation and immunoadjuvats (Payne 
et al. 1995). PCPP has three desirable properties. First, its size and physical 
characteristics facilitate uptake into mucosal lymphoid tissue where immune responses 
are stimulated. Second, PCPP is synthesized under very mild conditions so that 
antigenic integrity is maintained. Third, the hydrogel properties of PCPP allow a 
sustained Ag release over a long period (Allcock 1990; Andrianov 1998). Water-
solubility of PCPP salts, combined with a main chain that is easily degraded by 
hydrolytic reactions, enable PCPP to move from the injection site, thereby making PCPP 
attractive candidate for vaccine applications. PCPP combined with Ags is a potent 
immunoadjuvant for many vaccines such as influenza (Payne et al. 1998) and cholera 
vaccines (Wu et al. 2001). Mice immunized with vaccines containing PCPP, had IgM, 
IgG1, IgG2a, IgG2b, and IgG 3 ELISA antibody titers to influenza and cholera that were 
two to ten times higher than in mice immunized with the regular vaccine (Payne et al. 
1998; Wu et al. 2001). In mice infected with influenza, immune responses induced by 
PCPP were predominated by high levels of IL-4 and IgG 1 (Mutwiri et al. 2007). 
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Mutviri et al.  (2007)  also showed  that  adjuvant activities of  PCPP were greater than 
adjuvant activities of alum and were not influenced by the dose of Ag used. 
 
 
          1.6.2.2. Poly [di (sodium carboxylatoethylphenoxy) phosphazene] (PCEP)  
PCEP is a new polyphosphazene polyelectrolyte. PCEP significantly increases 
both IgG1 and IgG2a levels, which involve Th 1 and Th 2 humoral immune responses 
associated with production of both IFN-γ and IL-4 (Mutwiri et al. 2007). Andrianov et 
al. (2006) showed that PCEP could be used as a vaccine adjuvant as, like PCPP, it is 
capable of producing micro spheres as well. Microspheres are water-soluble and can 
extend PCEP utility in areas of mucosal immunization and controlled vaccine release 
(Andrianov et al. 2006). In addition, studies investigating the adjuvant activity of PCEP 
provide evidence that this polymer generates high immune responses. For example, in a 
study using influenza and hepatitis B surface Ags, mice injected with these Ags plus 
PCEP had IgG levels that were ten times higher than mice injected with PCEP 
(Andrianov et al. 2006). It has been shown that the adjuvant activities of PCEP are 
greater than those of PCPP (Mutwiri et al. 2007).  
PCEP’s degradability has been studied recently (Andrianov et al. 2006). This 
polymer degradation involves separation of side groups and formation of an unstable 
phosphazene resulting in the breakdown of the backbone (Andrianov et al. 2006). 
 
1.6.3.  Emulsigens®  
Emulsigen® is  oil-in-water  emulsion  that  contains  no  components of  animal 
origin.   Emulsigen®   creates   a   depot   at    the    injection   site   from  which   the   
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Ag   is released slowly, leading to prolonged stimulation of the immune system. At the 
same time, Emulsigen® also causes undesirable reactions at injection sites. Damage to 
tissues caused by Emulsigen® probably contributes to its adjuvant effects, as reducing 
the amount of Emulsigen® reduces both tissue damage and adjuvant activity (Vogel 
1995). 
Emulsigen® is widely applied in pharmaceuticals such as ointments and 
injections (Wedlock et al. 2005). The high solubilizing capacity of organic compounds 
in Emulsigen® combined with stability has made it an attractive vehicle for parental 
administrations (Park and Kim 1999). Emulsigen® is a licensed adjuvant that is 
extensively used in commercial veterinary vaccines. For example, piglets injected with a 
streptococci sp. vaccine that included Emulsigen® had higher levels of antigen-specific 
IFN-γ and lower levels of IL-4 in PBMCs than piglets injected with the regular vaccine 
(Linghua et al. 2006). These results suggest that TCs are activated and Th 1-based 
immune responses are induced (Linghua et al. 2006). Moreover, chickens showed 
increased antibody titers against ND when injected with an ND vaccine containing 
Emulsigen® compared with the regular ND vaccine (Hilgers et al. 1998). 
The efficiency of combining CpG-ODN and Emulsigen® to combat a variety of 
diseases in different species has been studied recently. A formulation combining CpG-
ODN with  Emulsigen®   enhanced   antibody  responses  to  an  equine influenza  virus 
vaccine (Lopez et al. 2006). This formulation also induced higher levels of IgG 1, IgG 2, 
and IFN-γ in response to streptococci sp. vaccine in swine than the regular vaccine   
(Linghua et al. 2006). Strong IFN-γ responses were measured in cattle vaccinated with 
Emulsigen® and CpG-ODN (Ioannou et al. 2002;  Wedlock et al. 2005) Mycobacterium  
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bovis and herpes virus glycoprotein vaccines that had been formulated.  
 
1.7.  Summary and objectives 
Infections with Salmonella and E. coli in humans and domestic animals are a 
worldwide problem. Salmonella Typhimurium and E. coli cause high mortality in 
neonatal chickens. The wide variety of sources of infection can contribute to the fact that 
these diseases are difficult to control with biosecurity practices, antibiotics, probiotics, 
and vaccination programs. Alternatives for antibiotics are needed, making novel 
prophylactic and therapeutic agents a priority for research in poultry. To fulfill this 
demand, the poultry industry is seeking new disease prevention and therapeutic agents to 
diminish the effects of these bacterial diseases.  
Unmethylated CpG-ODN have been known to express TLR 9 and stimulate 
innate immunity. It activates DCs, APCs, BCs proliferation, and macrophages and 
increases the production of IgM, IL-6, IL-12, and TNF. CpG-ODN have no apparent 
direct stimulatory effect on TCs, but they enhance the ability of APCs to activate TCs. 
Owing to the strength and nature of these effects, CpG-ODN have been tested for 
immune therapeutic and protective use. Immunostimulatory effects of CpG-ODN have 
been seen in a variety of viral, bacterial, and protozoan infections, among a range of 
vertebral species, including poultry. In 2003, for the first time Gomis et al. (3003) 
demonstrated that CpG-ODN had both local and systemic protective effects in broiler 
chicken against E. coli, a bacterium with an extracellular phase of survival, despite the 
fact that poultry does not express TLR 9. However, the effect of CpG-ODN against an 
interacellular bacterium remained to investigate. The first objective of this study was to 
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develop an animal model of Salmonella Typhimurium, an intracellular bacteria, in 
neonatal    broiler   chickens   with   a   mammalian   or   avian   isolates   of   Salmonella  
Typhimurium. This would facilitate the investigation of the immunostimulatory effect of 
CpG against this pathogen. The second objective of this study was to investigate  the 
effect of CpG-ODN treatment followed by dose titration of CpG-ODN and to study the 
duration of protection of CpG-ODN against Salmonella Typhimurium septicemia in 
neonatal broiler chickens. Thirdly, in ovo delivery of CpG-ODN in embryonated eggs 
against Salmonella Typhimurium in neonatal chicken was studied.  
Previously, it has been demonstrated that unformulated CpG-ODN delivered in 
ovo were potent immunostimulants against bacterial infections in neonatal chickens. The 
last objective of this study was to investigate if the immunoprotective effect of CpG-
ODN in neonatal chickens could be enhanced by formulating CpG-ODN with 
polyphosphazenes, liposomes or Emulsigen®. CpG-ODN are rapidly eliminated from 
the circulation due to absorption onto serum proteins and degradation by serum 
nucleases. Formulating  CpG-ODN with these adjuvants  might protect CpG-ODN from 
serum elimination and increase their duration of protection against pathogens. This was 
done using an E. coli challenge model. 
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2.0. DEVELOPMENT OF A CHALLENGE  MODEL OF  SALMONELLA  
       TYPHIMURIUM IN NEONATAL BROILER CHICKENS 
  
   2.1. Abstract 
Salmonella Typhimurium infection is a significant problem in the modern broiler 
industry due to high mortality in neonatal broiler chickens. The objective of this study 
was to develop a model of systemic Salmonella Typhimurium infection in neonatal 
broiler chickens with mammalian or avian isolates of Salmonella Typhimurium. Isolates 
of Salmonella Typhimurium from a mature chicken, a house sparrow (Passer 
domesticus), and a human were inoculated into groups of three-day-old broiler chickens. 
Groups of chickens received approximately 1x106, 1x107, or 1x109 cfu in the stationary 
or the logarithmic growth phase of Salmonella Typhimurium either by subcutaneous or 
oral routs (n = 20). Chickens were observed for ten days post-infection, during which 
clinical signs, mortality, and pathological lesions were observed and bacteria isolated. 
The mortality rate was 70% in neonatal broilers inoculated with either 1x106 or 1x107 
cfu of stationary phase of the human or chicken Salmonella Typhimurium isolate. In 
contrast, the mortality rate was 25% in broilers inoculated with either 1x106 or 1x107 cfu 
of stationary phase of the house sparrow Salmonella Typhimurium isolate. Oral 
administration of all three strains of  Salmonella Typhimurium  caused  5-30%  
mortality.  Mortality,  clinical  disease,  and  pathological 
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 lesions were caused by live Salmonella Typhimurium, not LPS.  In broiler chickens, the 
human or mature chicken isolates of Salmonella Typhimurium reproduced the clinical 
disease of salmonellosis with high repeatability, while the house sparrow isolate of 
Salmonella Typhimurium rarely reproduced clinical salmonellosis.   
 
 
 
 
   2.2. Introduction 
 
Salmonella Typhimurium is a gram negative, facultative intracellular pathogen. 
It can cause large economic losses in the poultry industry, primarily due to high 
mortality in neonatal chickens (Gast and Beard 1989), and epizootics in wild passerines 
(Refsum et al. 2003). Salmonella Typhimurium can be vertically transmitted to broiler 
chickens from infected parents (Gordon and Tucker 1965). Vertical transmission of 
Salmonella Typhimurium may result in increased mortality of embryos and neonatal 
chicks (Libby 2004). Horizontal transmission of Salmonella Typhimurium in poultry is 
associated with contaminated feed, rodents, insects and other vectors (Zecha 1977) 
(McAllister et al. 1994).  Eggshells contaminated with Salmonella Typhimurium can 
spread bacteria widely in the hatchery, thereby contaminating equipment and infecting 
newly hatched chickens (Gordon and Tucker 1965).  
Clinical signs of Salmonella Typhimurium infection in neonatal chickens include 
closed eyes, drooping wings, ruffled feathers (Gast 2003), anorexia, and emaciation 
(Barrow et al. 1987). Watery diarrhea accompanied by dehydration and pasting of the 
vent is also observed frequently (Gast 2003). Blindness (Padron 1990) and lameness 
(Barrow et al. 1987)  occur occasionally. Once a poultry  flock has been  infected  with 
Salmonella  Typhimurium, survivors serve as carriers of the bacteria, which colonize the 
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intestinal tract and are shed in feces for several weeks post infection (Gast and Beard 
1989; Beal et al. 2004).  
In contrast to neonatal chickens, older chickens infected with Salmonella 
Typhimurium can have enteric infections with mild or no clinical disease. At the time of 
processing, carcasses can therefore serve as a major source of Salmonella Typhimurium 
contamination of meat for human. Unfortunately, Salmonella Typhimurium control 
measures include strict biosecurity practices, use of antibiotics, and vaccination do not 
completely work and have limited success in older birds (Gast and Beard 1989; Beal et 
al. 2004).  
Salmonella Typhimurium causes high mortality in the genus Passeridae, 
especially in house sparrows (Passer domesticus) (Pennycott et al. 2006).  It appears 
that house sparrows acquire the infection primarily from their environment or other 
infected carriers (Refsum et al. 2003). There is a risk that house sparrows infected with 
Salmonella Typhimurium could in turn transmit the disease to humans, other domestic 
animals or poultry (Pennycott et al. 2006). 
Salmonellosis is an important food borne disease in humans in both developed 
and developing countries. In industrialized countries, paratyphoid Salmonella are an 
important cause of bacterial gastroenteritis (Haque et al. 2004). For example, 
Salmonella is estimated to cause 1.4 million illnesses and 600 deaths annually in the 
United States (Mead et al. 1999; Rice et al. 2003). Most human infections originate 
from contaminated food sources such as meat, milk, and egg. However, non food-borne 
infections occur due to contact with infected animals, contaminated water, or 
environmental contamination (Mead et al. 1999).  
 
 57
We have demonstrated previously that CpG-ODN stimulate innate immunity in 
neonatal broiler chickens against E. coli, a bacterium with an extracellular phase of 
survival (Gomis et al. 2004). In order to investigate the possible immunostimulatory 
effect of CpG-ODN against Salmonella Typhimurium, a bacterium with an intracellular 
phase of survival, we developed an animal model in neonatal broiler chicks with 
mammalian and avian isolates of Salmonella Typhimurium.  
 
 
2.3. Materials and methods 
 
      2.3.1. Bacteria   
Field isolates of Salmonella Typhimurium from a 25-week-old broiler breeder 
(D05-03438) and a house sparrow (D04-02959) with ingluveitis, cloacitis, hepatitis, and 
splenitis were obtained from the Prairie Diagnostic Services, University of 
Saskatchewan, Saskatoon, SK, Canada. A copy of the human isolate of Salmonella 
Typhimurium SL1344 was obtained from the Vaccine and Infectious Disease 
Organization, University of Saskatchewan, Canada. Aliquots of the bacteria were stored 
at –70οC in a 50% brain heart infusion broth (BHI) (Difco, Detroit, MI) supplemented 
with 25% (w/v) glycerol (VWR Scientific Inc., Montreal, QC). Bacteria to be used as 
the challenge were cultured on a Triple Sugar Iron Agar [(TSIA II with 5% sheep’s 
blood) Becton, Dickinson and Company Sparks, MD] for 18-24 hours at 37οC. Two to 
three colonies of bacteria were added to 200 ml of Luria Broth (LB) (Miller-BDH Inc.) 
in a one-L Erlenmeyer flask. To obtain Salmonella Typhimurium in the stationary 
phase, cultures were grown at 37οC for 16-18 hours with shaking at 200 rpm. The 
stationary   phase   cultures   contained   approximately   1x109    cfu/ml   of   Salmonella  
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Typhimurium after this incubation period. To prepare Salmonella Typhimurium in the 
logarithmic growth phase, a 1:1000 dilution of the stationary phase culture was added to 
100 ml of Luria Broth in a 500-ml Erlenmeyer flask and incubated at 37οC for three 
hours with shaking at 200 rpm. After shaking, the culture contained approximately 
1x109 cfu per ml of bacteria. These cultures were further diluted with saline to the 
concentration of bacteria required for challenge experiments. Serial dilutions were 
plated in duplicate on TSIA plates and  incubated for 18-24 hours at 37οC. Following 
incubation, bacterial colonies on the plates were counted to validate the challenge dose. 
 
      2.3.2. Animal model development 
All procedures involving animals were done according to a protocol approved by 
the University of Saskatchewan, Committee on Animal Care and Supply in accordance 
with regulations of the Canadian Council for Animal Care. Day-old broiler chickens 
were obtained from a local hatchery in Saskatchewan, Canada, and identified with 
individual neck tags (Swiftack Poultry Tags, Heartland Animal Health Inc., MO.). 
Groups of 20 chickens were randomly allocated to treatments and housed at the Animal 
Care Unit, Western College of Veterinary Medicine, University of Saskatchewan. Water 
and commercial broiler rations were provided ad libitum. Air was not re-circulated 
through rooms. The photoperiod was set at 24 hours per day for the first three days and 
16 hours per day for the remaining seven days.  Room temperature was maintained at 30 
-32 ○C for the first week and 28-30 ○C for the second week. Three-day-old chickens 
were  challenged  with Salmonella Typhimurium  isolates subcutaneously in the neck or  
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orally using 18-gauge gavage needle.       
            Birds  were  observed for ten days  following challenge.  Daily clinical scores for  
each bird was given using the following categories: 0 = normal; 1 = hesitant to move 
and easily fatigued; 2 = unable to stand or forage for food and therefore euthanized; 3 = 
dead. Cumulative clinical scores (CCSs) for each bird (CCS/Bird) and for each group of 
20 (CCS/Group) were calculated as follows:  
CCS/Bird- Clinical scores were summed for each bird across the ten days of the 
trial. Birds that had been euthanized were given a score of 2 for the day of euthanasia 
and 3 for each day remaining in the trial. Dead birds were given a score of 3 for each 
day remaining in the trial, including the day of death.  
CCS/Group- Clinical scores for each bird were summed across groups of 20 
birds to give a CCS for each group.  
Mortality was recorded daily. Dead or euthanized birds were necropsied 
immediately. Gross lesions of pericarditis, perihepatitis, airsacculitis and polyserositis 
were recorded. Bacterial swabs were taken from air sacs and cultured on TSIA plates. 
Growth on the plates was recorded as follows: 0 = no growth; +1 = growth of bacteria 
on area 1; +2 = growth of the bacteria on areas 1 and 2; +3 = growth of bacteria on areas 
1, 2 and 3; and +4 = growth of bacteria on areas 1, 2, 3 and 4 (Barry 1972). 
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      2.3.3. Experimental design 
         (a) Virulence of Salmonella Typhimurium isolated from avian and 
 
               mammalian hosts  
 
Three  groups  of  60  chickens  were  inoculated  with  Salmonella Typhimurium 
isolated from chicken, house sparrow or human subjects (Table 2.1). Each treatment 
group was divided into four sub-groups of 20 chickens; I- two groups were injected 
subcutaneously (neck) with either 1x106 or 1x107 cfu /ml of stationary phase Salmonella 
Typhimurium, II- the third group was injected subcutaneously (neck) with 
approximately 1x106 cfu of logarithmically growing Salmonella Typhimurium,  III- the 
fourth group was orally administered approximately 1x109 cfu of logarithmically 
growing Salmonella Typhimurium. As described above, clinical signs were observed 
and bacteria cultured daily. 
 
 
 Table 2.1. Groups of neonatal broiler chickens challenged with different isolates of 
                   Salmonella Typhimurium 
 
Salmonella 
Typhimurium 
isolate 
 / group 
 
 
 
Treatment 
 
Phase of 
Salmonella 
Typhimurium 
Dose of 
Salmonella 
Typhimurium 
cfu / ml 
 
 
Route of 
administration 
 
Number 
of birds 
/ group 
 
 
Chicken 
 
1 
2 
3 
4 
 
Stationary 
Stationary 
Logarithmic 
Logarithmic 
 
2.0x10 6 
2.0x10 7 
2.0x10 6 
2.0x10 9 
 
Subcutaneous 
Subcutaneous 
Subcutaneous 
Oral 
 
20 
20 
20 
20 
 
 
House 
sparrow 
 
1 
2 
3 
4 
 
Stationary 
Stationary 
Logarithmic 
Logarithmic 
 
1.1x10 6 
1.1x10 7 
1.1x10 6 
1.1x10 9 
 
Subcutaneous 
Subcutaneous 
Subcutaneous 
Oral 
 
20 
20 
20 
20 
 
 
Human 
 
1 
2 
3 
4 
 
Stationary 
Stationary 
Logarithmic 
Logarithmic 
 
1.5x10 6 
1.5x10 7 
1.5x10 6 
1.5x10 9 
 
Subcutaneous 
Subcutaneous 
Subcutaneous 
Oral 
 
20 
20 
20 
20 
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         (b) Dose titration of Salmonella  Typhimurium isolated from a chicken 
 
Three-day-old broiler chicks were randomly allocated into four groups, each 
containing 20 birds. Birds in each group were inoculated subcutaneously (neck) with 
1.2x105, 1.2x106, 1.2x107, or 1.2x108 cfu /ml of stationary phase culture of Salmonella 
Typhimurium isolated from a chicken. Clinical signs were recorded and bacteria 
cultured as described above 
To determine if the clinical salmonellosis and pathological lesions observed in 
chickens inoculated with the chicken isolate were associated with live Salmonella 
Typhimurium septicemia and not LPS, the following trial was conducted. At three days 
age, ten birds were challenged subcutaneously (neck) with 1.5x108 cfu of killed 
Salmonella Typhimurium. To kill the bacteria, LB containing 1.5x108 cfu of Salmonella 
Typhimurium was left at room temperature for three days. It was then incubated for one 
hour at 65°C and kept in the fridge for another two days. The broth was cultured on 
TSIA plates to confirm the death of the bacteria. Birds were observed for ten days post 
inoculation.  
 
      2.3.4. Statistical analysis 
The survival pattern and median survival were compared using log-rank tests and 
chi-square statistics. Survival data was analyzed using Prism (Prism 4.0, GraphPad 
Software Inc., San Diego, CA. USA www.graphpad.com). The clinical score for each 
bird was summed over the ten-day observation period. Median scores were compared 
among groups using a Kruskal-Wallis test. 
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2.4. Results  
       (a) Virulence of Salmonella Typhimurium isolated from avian and   
             mammalian hosts 
Chicken isolate-  
Mortality  was similar  in birds  inoculated  subcutaneously with  logarithmically 
  growing   Salmonella Typhimurium   and   those  inoculated  by   the  same  route  with 
stationary Salmonella Typhimurium (Fig. 2.1). The lowest mortality rate was observed 
in chickens orally challenged with logarithmically growing Salmonella Typhimurium 
(Fig. 2.1). Groups inoculated subcutaneously with either 2x106 and 2x107 cfu of 
stationary, or 1x106 cfu of logarithmically growing Salmonella Typhimurium had 
cumulative clinical scores (CCS/Group) of 226, 389 and 317 respectively. The CCS of 
the group orally inoculated with 1x109 cfu of Salmonella Typhimurium was 163 (Fig. 
2.4). Salmonella Typhimurium isolates from the air sacs of neonatal broiler chickens in 
the groups inoculated using subcutaneous or oral routes with different doses and 
different phases of culture are shown in Table 2.2. 
 Human isolate- The group that was subcutaneously inoculated in the neck with 
logarithmically growing phase of Salmonella Typhimurium had a survival rate that was 
between the survival rates of the groups that were inoculated subcutaneously with either 
1.5x106 or 1.5x107 cfu of stationary phase Salmonella Typhimurium. The mortality rate 
was the lowest for the group that was orally challenged with logarithmically growing 
Salmonella Typhimurium (Fig. 2.2). Birds that were inoculated subcutaneously with 
either 1.5x106 and 1.5x107 cfu of stationary phase or 1.5x106 cfu of logarithmically 
growing Salmonella Typhimurium had CCS (per group) of 157, 406 and 331 
respectively  (Fig. 2.4). The  CCS  of the  group  that was orally inoculated with 1.5x109  
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Fig.  2.1. Survival of chickens following challenge with a chicken isolate of Salmonella 
Typhimurium.  Birds  were inoculated  subcutaneously with  2x106  cfu  (■)  or  2x107  
cfu  (○) of stationary    phase,    1x106  cfu (▲) of  log  phase, or  orally  with  1x109  (x) 
log phase of cultures (n = 20). 
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Fig. 2.2. Survival of chickens following challenge with a human isolate of Salmonella 
Typhimurium.  Birds were inoculated   subcutaneously with  1.5x106  cfu (■) or  1.5x107 
cfu  (○)  of stationary   phase,   1.5x106  cfu (▲) of  log  phase, or orally with 1.5x109 (x) 
log  phase  of cultures (n = 20).   
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Fig. 2.3. Survival  of  chickens  following  challenge  with  a  house  sparrow  isolate of 
Salmonella Typhimurium.  Birds were inoculated  subcutaneously with 1.1x106 cfu (■) or  
1.1x107  cfu  (○)  of  stationary   phase,   1.5x106  cfu  (▲) of  log   phase, or  orally  with 
1.5x109 (x) log phase  of cultures (n = 20).   
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Table 2.2. Level of Salmonella Typhimurium isolated from the air sacs of the birds 
                  following challenge with chicken, house sparrow, and human isolates. 
 
Salmonella 
Typhimurium 
isolate/ 
group/ 
 
Phase of 
Salmonella 
Typhimurium 
Dose of 
Salmonella 
Typhimurium 
cfu / ml 
 
 
Route of 
administration 
 
 
 
0 
 
Growth 
 
+1 
 
(Score A) 
 
   +2 
 
 
 
 
+3 
 
 
 
+4 
 
 
Chicken 
 
Stationary 
Stationary 
Logarithmic 
Logarithmic 
 
2.0x10 6 
2.0x10 7 
2.0x10 6 
2.0x10 9 
 
Subcutaneous 
Subcutaneous 
Subcutaneous 
Oral 
 
  5 * 
1 
3 
10 
 
8 
5 
9 
7 
 
6 
10 
6 
3 
 
1 
2 
0 
0 
 
0 
2 
2 
0 
 
House 
sparrow 
 
Stationary 
Stationary 
Logarithmic 
Logarithmic 
 
1.1x10 6 
1.1x10 7 
1.1x10 6 
1.1x10 9 
 
Subcutaneous 
Subcutaneous 
Subcutaneous 
Oral 
 
10 
2 
8 
14 
 
8 
16 
11 
6 
 
1 
2 
1 
0 
 
1 
0 
0 
0 
 
0 
0 
0 
0 
 
 
Human 
 
Stationary 
Stationary 
Logarithmic 
Logarithmic 
 
1.5x10 6 
1.5x10 7 
1.5x10 6 
1.5x10 9 
 
Subcutaneous 
Subcutaneous 
Subcutaneous 
Oral 
 
3 
0 
3 
15 
 
12 
8 
8 
5 
 
5 
11 
6 
0 
 
0 
1 
1 
0 
 
0 
0 
2 
0 
 
Salmonella Typhimurium isolated from air sacs of neonatal broiler chickens. Groups 
were inoculated by subcutaneous or oral routes with different doses and different phases 
of culture, as shown in this table. 
 A Salmonella Typhimurium growth on the TSIA plates was scored as follows: 0 = no 
growth; +1 = growth of bacteria on area 1; +2 = growth of the bacteria on areas 1 and 2; 
+3 = growth of bacteria on areas 1, 2, and 3; +4 = growth of bacteria on areas 1, 2, 3, 
and 4 (n = 20). 
* Number of birds. 
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Fig. 2.4. Cumulative clinical scores (CCSs) for individual birds following subcutaneous 
challenge with different isolates of Salmonella Typhimurium. CCSs of birds inoculated 
with 1x106  (■,□,х), 1x107 (▲,∆,+) cfu of stationary phase culture, 1x106 (▼,○, *) and 
1x109 (●,◊, ׀) cfu of log phase culture of Salmonella Typhimurium [Ch = chicken, Hsp = 
house  sparrow,  Hu = human, SQ = subcutaneous, Log = logarithmic] (Bar = median)  
(n = 20).   
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cfu Salmonella Typhimurium was 72 (Fig. 2.2).  
 House sparrow isolate- Chickens inoculated subcutaneously (neck) with 
stationary phase Salmonella Typhimurium had the highest mortality rate of 25%. Birds 
subcutaneously inoculated with logarithmically growing Salmonella Typhimurium 
hadthe lowest mortality rate (Fig. 2.3). The CCS of groups inoculated subcutaneously 
with either 1.1x106 and 1.1x107 cfu of stationary phase or 1.5x106 cfu of logarithmic 
phase Salmonella Typhimurium were 67, 142 and 21, respectively. The CCS of the 
group orally inoculated with 1.5x109 cfu Salmonella Typhimurium was 61 (Fig. 2.4).  
 
       (b) Dose titration of Salmonella Typhimurium isolated from a chicken  
Typically, birds inoculated with 1.2x108 cfu of Salmonella Typhimurium had 
acute septicemia and died or were euthanized 24-72 hours post-challenge. Pathological 
lesions that were observed in this animal model were pericarditis, airsacculitis, 
perihepatitis and polyserositis. Birds inoculated with 1.2x107 cfu of Salmonella 
Typhimurium had moderate to severe lesions in the air sacs and other serosal surfaces 
(mentioned above). In contrast, birds that received either 1.2x105 or 1.2x106 cfu of 
Salmonella Typhimurium had mild to moderate lesions in the air sacs and other serosal 
surfaces (mentioned above) (Fig. 2.7). Salmonella Typhimurium was isolated from 
100% of lesions in the air sacs of birds that died of septicemia between days one and ten 
post-challenge. The CCS of the group inoculated with 1.2x108 cfu of Salmonella 
Typhimurium was high (563), compared to groups inoculated with 1.2x105 (70), 1.2x106 
(95), and 1.2x107 (193) cfu of Salmonella Typhimurium (Fig. 2.6). Bacterial isolation 
results are shown in Table 2.3.  
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 Fig. 2.5. Survival of neonatal chickens following challenge with stationary phase 
Salmonella Typhimurium isolated from a chicken. Survival of three-day-old chickens 
following challenge with 1.2x105 (▲), 1.2x106 (■), 1.2x107 (●) or 1.2x108 (▼) cfu of a 
chicken isolate of Salmonella Typhimurium by subcutaneous injection in the neck (n = 
20).  
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Fig. 2.6. Cumulative clinical scores (CCSs) of individual birds following subcutaneous 
challenge with a chicken isolate of Salmonella Typhimurium. The CCS of individual 
birds that had been subcutaneously inoculated with different doses of stationary phase 
Salmonella Typhimurium is shown in this graph (Bar = median) (n = 20).  
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Table 2.3. Level of  Salmonella Typhimurium  isolated  from  the  air  sacs  of  neonatal 
                  chickens following challenge with various doses of Salmonella Typhimurium 
                  isolated from a chicken 
                                   
                                                                             Number of birds with 
Salmonella Typhimurium                       Salmonella Typhimurium growth  
    challenge dose (cfu)                                                (score A) 
                      
                                                             0            +1            +2             +3             +4 
 
             1.2x10 5                                 13             4              2               1                0 
             1.2x10 6                                 11             4              3               2                0 
             1.2x10 7                                  5              6              5               3                1 
             1.2x10 8                                  0              0              5              10               5 
 
 
Birds were subcutaneously inoculated with stationary phase Salmonella Typhimurium at 
day three of age. Isolation of Salmonella Typhimurium from the air sacs of the neonatal 
broiler chickens in the groups inoculated with different doses of cultures are shown in 
this table. 
 A Salmonella Typhimurium growth on the TSIA plates were scored as follows: 0 = no 
growth; +1 = growth of bacteria on area 1; +2 = growth of the bacteria on area 1 and 2; 
+3 growth of bacteria on area 1, 2, and 3; +4 = growth of bacteria on area 1, 2, 3, and 4 
(n = 20). 
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Fig. 2.7. Pericarditis, perihepatitis, and airsacculitis (polyserositis) of a neonatal broiler 
chicken following 1x106 cfu of Salmonella Typhimurium challenge. Salmonella 
Typhimurium isolate originated from a broiler chicken with a field case of 
salmonellosis. 
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  (a)  Lung                                                           (b)  Liver 
                                 
                                (c)  Spleen 
   
Fig. 2.8. Histopathological lesions of the lung, liver and spleen in a bird inoculated with 
Salmonella Typhimurium. Colonies of bacteria in the blood vessels of the lung (a), 
sinusoids of the liver (b), and red and white pulp of the spleen (c) in neonatal broiler 
chickens following subcutaneous inoculation with 1.2x106 cfu of stationary phase 
Salmonella Typhimurium.  
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The survival of the birds that had been subcutaneously inoculated with killed Salmonella 
Typhimurium was 100%. No bacteria were isolated from TSIA plates. 
 
2.5. Discussion  
Salmonella Typhimurium is a common serotype associated with high mortality 
in neonatal broiler chickens (Gast and Beard 1989). In contrast, Salmonella infection in 
adult poultry leads to colonization of the gastrointestinal tract and shedding with no 
apparent clinical disease or mortality but increased risk of carcass contamination 
(Henzler et al. 1994; Libby 2004). Controlling Salmonella in the poultry industry is a 
priority due to its association with food borne infections in humans. Moreover, control 
of Salmonella with antibiotics has been linked to the emergence of antibiotic resistant 
strains of bacteria (Ngwai et al. 2006). Although Salmonella control programs such as 
biosecurity, probiotics and vaccination have been implemented in broiler breeder, 
broiler grow-out and processing, success of control programs has been limited (Gast 
2003). 
The objective of this study was to develop an animal model of Salmonella 
Typhimurium in neonatal broiler chickens with mammalian or avian isolates. 
Salmonella Typhimurium isolates from a chicken, a house sparrow and a human were 
used in this study. We were able to reproduce Salmonella Typhimurium septicemia in 
neonatal broiler chickens with both chicken and human isolates. The gross and 
microscopic lesions, mortality and clinical signs observed in this study are typical 
findings in field cases of Salmonella Typhimurium. In contrast, the house sparrow 
isolate  of  Salmonella Typhimurium  did  not  reproduce  clinical  disease, regardless  of  
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dose, route of administration or phase of growth. It is possible that the house sparrow 
isolate of Salmonella Typhimurium lacks virulent factors necessary to elicit clinical 
disease  in neonatal  broiler chickens  (Skyberg  et al. 2006). Polymerase  chain  reaction  
(PCR)  analysis  of  15  genes  identified  as  putative virulence factors  revealed  that all 
genes tested were present in human and broiler isolates of Salmonella Typhimurium. In 
contrast, the house sparrow isolate lacked the prgH gene found in the SPI-1 and sifA 
genes, which is a secreted effecter protein (personal communication-Allan, B). If this 
isolate is typical of other isolates from wild birds, then there is little risk that wild birds 
would transmit salmonellosis to poultry. However, it is impossible to speculate on the 
characteristics of Salmonella caused by wild birds based on a single isolate. Clinical 
salmonellosis and pathological lesions in this animal model were associated with live 
Salmonella Typhimurium septicemia and not with LPS of Salmonella Typhimurium as 
neonatal chickens were inoculated with 100 times more killed Salmonella Typhimurium 
than the normal challenge dose. No clinical signs or pathological lesions were observed.  
All birds inoculated with 1x108 cfu of Salmonella Typhimurium isolated from a 
chicken died within three days due to septicemia. The mortality rate in this group was 
considered too high to be useful for further studies. In contrast, the survival rate of the 
1x107 cfu group was 40%, which could be useful in developing an animal model for 
future studies. As the survival rates of groups given 1x105 and 1x106 cfu were similar 
(80 and 85%), 1x106 and 1x107 cfu with one log difference were chosen for the animal 
model. 
Both stationary and logarithmic phases of Salmonella Typhimurium produced 
disease  in   neonatal   chicken.   However,  survival    rates   of  chickens  injected   with  
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logarithmic phase Salmonella Typhimurium (1x06 cfu) of different isolates were either 
similar or intermediate to the two doses of stationary phase Salmonella Typhimurium 
(1x106 and 1x107 cfu). 
This animal  model mimicked the clinical signs and  pathological lesions seen in 
commercial poultry attributed to Salmonella Typhimurium infection. This model 
provides a valuable tool for studying pathogenesis and control of salmonellosis in young 
poultry. Although the mortality rate using this animal model is higher than that for field 
cases of salmonellosis, the gross and histopathological lesions are representative of the 
natural disease of salmonellosis in poultry. This animal model will facilitate studies on 
the interactions between Salmonella Typhimurium and the innate immune system of 
neonatal broiler chickens.  
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3.0. DELIVERY OF  CPG-ODN  TO  EMBRYONATED  EGGS  TO  PROTECT  
        NEONATAL  CHICKENS  AGAINST  SALMONELLA  TYPHIMURIUM 
        INFECTION 
   3.1. Abstract 
Oligodeoxynucleotides (ODN) containing CpG motifs (CpG-ODN) have been 
shown to stimulate the innate immune system against viral, bacterial and protozoan 
infections in many vertebrate species. The objective of this study was to investigate the 
immunostimulatory effect of CpG-ODN against Salmonella Typhimurium septicemia in 
neonatal broilers. Day-old broiler chicks, or embryonated eggs that had been incubated 
for 18 days, received 50 μg of CpG-ODN, 50 μg of non-CpG-ODN, or saline. Four days 
after exposure to CpG-ODN or day two-post hatch, 1x106 or 1x107 cfu of a virulent 
Salmonella Typhimurium isolate was inoculated subcutaneously into the neck. Clinical 
signs, pathology, bacterial isolations from air sacs, and mortality were observed for ten 
days following challenge with Salmonella Typhimurium. The survival rate of birds in 
groups receiving either non-CpG-ODN or saline following Salmonella Typhimurium 
infection was 40-45%. In contrast, birds receiving CpG-ODN had a significantly higher 
survival rate of 80-85% (P < 0.0001). Bacterial loads and pathology were lower in 
groups treated  with   CpG-ODN  than  groups  treated  with  saline  or  non-CpG-ODN.  
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 Colony forming units of Salmonella Typhimurium in the peripheral blood were 
significantly lower in birds treated with CpG-ODN than in the group treated with saline. 
This is the first time that immunoprotective effect of CpG-ODN against an intracellular 
bacterial infection has been demonstrated in neonatal broiler chickens following in ovo 
delivery.  
 
3.2. Introduction 
The innate immune system of vertebrates recognizes structurally conserved 
PAMPs and allows immediate host immune responses to limit infection (Medzhitov and 
Janeway 2002). Bacterial and viral DNA are among PAMPs recently found to stimulate 
the innate immune system and afford immune protection against microbial infections in 
vertebrate species (Ashkar and Rosenthal 2002; Krieg 2002; Mutwiri et al. 2003). In 
contrast to vDNA, bDNA contains relatively abundant unmethylated CpG dinucleotides 
(Bird 1993). These unmethylated CpG dinucleotides within specific flanking bases 
(overall referred to as CpG motif) are now known to be the molecular basis that 
contributes to the immunostimulatory activity of bDNA (Ahmad-Nejad et al. 2002). 
Synthetic oligonucleotides containing the CpG motif (CpG-ODN) mimicking bDNA 
have been demonstrated to retain immunostimulatory activities (Yamamoto et al. 1992). 
TLR 9, a member of an innate immune receptor family, has been identified and is 
known to recognize bDNA or CpG-ODN and initiates the signaling cascade leading to 
various innate immune responses in murine and human immune cells (Hemmi et al. 
2000; Bauer et al. 2001). Recently, studies have also shown the immune stimulatory 
activities of CpG-ODN in other vertebrate species including fish (Jorgensen et al. 2001; 
Meng et al. 2003; Carrington and Secombes 2006), chickens (Vleugels et al. 2002; 
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Gomis et al. 2003; He et al. 2003; He and Kogut 2003; Gomis et al. 2004; He et al. 
2005a; He et al. 2005b), pigs (Kamstrup et al. 2001), cattle (Zhang et al. 2001), and 
sheep (Mena et al. 2003).  
CpG-ODN stimulate the immune system to mount a rapid innate immune 
response and promotes the development of Th 1- type protective immunity. Due to the 
strength and nature of this stimulation, CpG-ODN have been tested for immune 
therapeutic and protective use (Klinman et al. 1999a; Krieg 2002). For example, use of 
CpG-ODN in a murine model has been shown to have immunoprotective and 
immunotherapeutic effects against bacterial infections caused by Listeria 
monocytogenes (Krieg et al. 1998; Klinman et al. 1999b), Francisella tularensis 
(Klinman et al. 1999b), Klebsiella pneumoniae (Deng et al. 2004), and Burkholderia 
pseudomallei (Wongratanacheewin et al. 2004). In addition, immunoprotective effect of 
CpG-ODN against parasitic protozoan infections caused by Leishmania major 
(Zimmermann et al. 1998), Plasmodium yoelii and Plasmodium falciparum (Gramzinski 
et al. 2001), and Leishmania donovani (Datta et al. 2003) has been investigated in mice 
as well. Several studies have also demonstrated that CpG-ODN have antiviral activities 
(Harandi et al. 2003; Schlaepfer et al. 2004).  
Salmonella Typhimurium is a facultative intracellular pathogen capable of 
causing disease in a wide range of host species (Gast 2003). It is the primary cause of 
high mortality in neonatal chickens (Gast 2003). In older chickens, however, this 
serotype causes enteric infection, inflammatory diarrhea with a mild mortality and no 
clinical disease (Gast 2003). Primary infection of chickens one to three days of age with 
Salmonella Typhimurium has  pronounced effects on  the persistence of enteric infection 
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(Beal  et al.  2004).   Control  of   Salmonella Typhimurium  in  young  infected  birds  is 
 complicated because it leads to colonization of the intestinal tract and shedding of 
Salmonella Typhimurium in feces for several weeks without clinical disease. As a result, 
Salmonella is present in the intestine when chicken are processed, thereby increasing the 
risk that carcasses be contaminated, potentially transmitting Salmonella Typhimurium to 
humans. Control measures, including strict biosecurity, the use of antibiotics, probiotics, 
and vaccination programs increase production expenses and do not successfully 
eliminate Salmonella from contaminated houses (Zecha et al. 1977).  
It has been shown that chemokines and cytokines play a key role in the 
protective response to Salmonella. Clearing primary infections of Salmonella 
Typhimurium in chickens appears to involve IFN-γ mediated TC (primarily Th 1) 
responses (Withanage et al. 2005). However, the mucosal immune system of chickens 
does not fully mature until some weeks after hatching (Libby 2004). Indeed, the enteric 
immune system is poorly developed in newly hatched chickens, which experience 
severe systemic disease if challenged with Salmonella Typhimurium under three days of 
age (Barrow et al. 1987). Therefore, stimulating the innate immune system of neonatal 
chickens against bacterial pathogens would be beneficial to the poultry industry. 
Recently, it has been demonstrated that CpG-ODN have an immunoprotective 
effect against E. coli, which causes an extracellular bacterial infection in neonatal broiler 
chickens (Gomis et al. 2004). However, little is known about the effect of CpG-ODN 
against intracellular bacterial infections in chickens (He et al. 2005). Specifically, the 
use of CpG-ODN in embryos to fight intracellular bacterial infections has not been 
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studied. The objective of this study is to investigate the imunostimulatory effect of CpG-
ODN against Salmonella Typhimurium infections in neonatal chickens.  
 
   3.3. Materials and methods 
      3.3.1. Salmonella Typhimurium culture and animal model development.  
A field isolate of Salmonella Typhimurium taken from a 25-week old broiler 
chicken (Prairie Diagnostic Services number (05-03438) was used as the challenge 
strain. Aliquots of bacteria were stored at –70οC in 50% BHI (Difco, Detroit, MI) 
supplemented with 25% (wt/vol) glycerol (VWR Scientific Inc., Montreal, Quebec, 
Canada). Bacteria for use as the challenge were cultured on a Triple Sugar Iron Agar 
plate (TSIA) with 5% sheep’s blood (Becton Dickinson and Company Sparks, MD) for 
18-24 hours at 37οC. Two to three colonies of bacteria from the agar plate were added to 
200 ml of Luria Broth (LB) (Miller, BDH Inc.) in a one-L Erlenmeyer flask. The culture 
was grown at 37οC for 16-18 hours with shaking at 200 rpm. At this time, the culture 
contained approximately 1 x 109 cfu/ml of stationary phase Salmonella Typhimurium. 
The cultures were further diluted in saline to the concentration of bacteria required for 
challenge experiments. Birds were challenged subcutaneously in the neck with either 
1x106 or 1x107 cfu of Salmonella Typhimurium in 250 μl of saline. Serial dilutions of 
the culture were plated on TSIA plates in duplicate and incubated for 18-24 hours at 
37οC. The number of colonies was then counted to validate the challenge dose.  
All procedures involving animals were done according to the protocol approved 
by the University of Saskatchewan Committee on Animal Care. Day-old broiler 
chickens  or  eggs  were  obtained  from  a  local hatchery in Saskatchewan, Canada, and 
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 identified individually with neck tags (Swiftack Poultry Tags, Heartland Animal Health 
Inc., MO). Groups containing 20 day-old chickens were randomly assigned to individual 
animal   isolation  chambers  at  the Animal  Care Unit, Western  College  of  Veterinary 
 Medicine, University of Saskatchewan. Water and commercial broiler ration were 
provided ad libitum. Air from each room was removed by a HEPA filter and replaced 
with non-recirculated air at the rate of 18 changes/hour. Air pressure differentials were 
maintained and strict sanitary practices followed for the duration of the experiment. A 
photoperiod of 24 hours per day for the first three days and 16 hours per day for the 
remaining seven days was established. Room temperature was maintained at 30-32 ○C in 
the first week and 28-30 ○C in the second week. 
Clinical signs in birds were observed twice daily for ten days following 
challenge with Salmonella Typhimurium. Daily clinical scores for each bird were 
assigned as follows: 0 = Normal; 1= hesitant to move and rapidly fatigued; 2 = unable to 
stand or forage for food and therefore euthanized; 3 = found dead. Cumulative clinical 
scores (CCSs) for each bird (CCS/Bird) and for each group of 20 (CCS/Group) were 
calculated as follows:  
CCS/Bird- Clinical scores were summed for each bird across the ten days of the 
trial. Birds that had been euthanized were given a score of 2 for the day of euthanasia 
and 3 for each day remaining in the trial. Dead birds were given a score of 3 for each 
day remaining in the trial, including the day of death.  
CCS/Group- Clinical scores for each bird were summed across groups of 20 
birds to give a CCS for each group.  
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Mortality was recorded every day. Dead or euthanized birds were necropsied 
immediately. Gross lesions such as pericarditis, perihepatitis, airsacculitis and 
polyserositis were recorded.  Bacterial swabs were taken from the air sacs and cultured 
on TSIA plates. Growth on the plates was recorded as follows: 0 = no growth; +1 = 
growth of bacteria on area 1; +2 = growth of the bacteria on areas 1 and 2; +3 = growth 
of bacteria on areas 1, 2 and 3; and +4 = growth of bacteria on areas 1, 2, 3 and 4 (Barry 
1972). 
 
3.3.2. Synthetic CpG-ODN  
The  sequence of  CpG-ODN  used  was TCGTCGTTGTCGTTTTGTCGTT  and 
the sequence of non-CpG-ODN was TGCTGCTTGTGCTTTTGTGCTT. Both ODNs 
were free of endotoxin and produced with a phosphorothioate backbone (provided by 
Qiagen-GmbH, Hilden, Germany). Synthetic CpG-ODN was diluted in sterile, pyrogen 
free saline and administered in a 100 μl volume either in ovo into the amniotic cavity 
through the air cell of the egg using a 20-gauge one-inch needle or intramuscularly into 
the leg of hatched chicks. The volume injected and the needle length were selected to 
simulate in ovo technology used in the poultry industry.  
 
 
      3.3.3. Experimental design 
         (a) Effect of treatment with CpG-ODN and dose titration of CpG-ODN on  
              Salmonella  Typhimurium infection in neonatal broilers  
  The objective of this experiment was to investigate the protective effect of CpG-
ODN  and  the  dose titration of CpG-ODN against  Salmonella Typhimurium  infection. 
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 Based on previous data on the effectiveness of CpG-ODN against E. coli (Gomis et al. 
2004), 50 μg of CpG-ODN was selected as the standard dose. Day-old broiler chickens 
were randomly allocated to one of seven groups, each containing 20 birds. Birds in each 
group were identified with neck band and injected in the leg with CpG-ODN (50, 10,  or 
1 μg per bird), non-CpG-ODN (50, 10, or 1 μg per bird), or saline. All groups were 
challenged at four days of age with 1x107 cfu of Salmonella Typhimurium, as described 
previously. Clinical evaluations were made and bacteria isolated as described above.  
 
 
         (b) Duration of CpG-ODN protection against Salmonella Typhimurium 
infection in neonatal broiler chickens  
Day-old broiler chicks were randomly allocated to one of eight groups, each 
containing 20 birds. Birds in each group were individually identified with neck bands, 
and injected with 50 μg of CpG-ODN intramuscularly in the leg on one of the following 
days of age: 1, 2, 3, 4, 6, 8, or 9. All groups were challenged on day 9 of age with 
1.1x108 cfu of Salmonella Typhimurium as described above. Clinical evaluations were 
made and bacteria isolated as described above. 
 
 
         (c) Effect of CpG-ODN on Salmonella  Typhimurium septicemia 
Birds were randomly allocated to one of two groups of 80 birds and housed in an 
animal isolation room. At one day of age, groups were injected intramuscularly in the 
leg with 50 μg of CpG-ODN or saline. All birds were challenged on day three with 
1.2x106 cfu of Salmonella Typhimurium as described above. One ml of blood was 
collected from the suboccipital  cavernous sinus (atlantooccipital sinus) of three 
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anesthetized birds into three ml syringes containing 250 μl heparin (Organon Teknika, 
Toronto, Canada)  at 1, 6, 12, 18, 24, 36, 48  hours,  3, 4, 5, 6, and 7 days  post-challenge 
 with Salmonella Typhimurium. The birds were subsequently euthanized with halothane 
(Halocarbon Products Corporation Rivin Edge, NJ) at each time point. The number of 
bacteria in individual blood samples was determined by plating ten-fold serial dilutions 
in duplicate on TSIA plates and incubating them at 37oC for 24 hours. The threshold of 
detection was 100 cfu per ml. During the course of this experiment, mortality was 
observed in both the treatment and control groups. Birds that survived were randomly 
selected at each time point. 
 
 
         (d) Effect of CpG-ODN administered in ovo at day 18 of incubation followed 
by challenge with Salmonella Typhimurium at hatching   
In ovo  administration  is known to be a safe, efficacious and convenient  method 
for vaccinating poultry (Ricks et al. 1999). Embryonated eggs were randomly allocated 
to one of three groups, each containing 25 eggs. On day 18 of incubation, groups were 
inoculated with 50 μg of CpG-ODN, 50 μg of non-CpG-ODN or saline. All groups were 
challenged with 1.1x106 cfu of Salmonella Typhimurium on day two post-hatch as 
described above. Clinical scores were assigned and bacteria isolated as in previous 
experiments.  
 
      3.3.4.  Statistical analysis 
Survival patterns and median survival times were compared using log-rank tests 
and  chi-square  statistics. Survival data  was analyzed using  Prism (Prism 4.0, GraphPad 
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 Software Inc., San Diego, CA. USA www.graphpad.com) with α = 0.05. Clinical scores 
for each bird were summed over the ten-day observation period and the differences 
among groups were tested using Krukal-Wallis non-parametric analysis of variance. 
Blood samples taken simultaneously from treatment and control groups were compared 
using the non-parametric Wilcoxon signed rank test. The effect of CpG treatment on 
development of septicemia was evaluated using Wilcoxon rank sum tests and 
proportional hazards regression analysis (Statistic 7, Analytical Software, Tallahassee 
FL). 
 
3.4. Results 
(a) Effect of treatment with CpG-ODN and dose titration of CpG-ODN on 
      Salmonella Typhimurium infection in neonatal broilers             
 The survival rate of birds treated with 50 μg of CpG-ODN was higher than in 
groups treated with 10 or 1 μg of CpG-ODN, 50, 10, or 1 μg of non-CpG-ODN or saline 
(p< 0.01) (Fig. 3.1). Cumulative clinical score (CCS) differed significantly among 
groups (p<0.001). Comparison of mean CCS ranks by group revealed that the CCS of 50 
μg CpG-ODN group differed significantly from the CCS of other groups (p<0.05) (Fig. 
3.2). The group treated with 50 μg of CpG-ODN (CCS of 195) had a significantly lower 
CCS than other groups (10 μg  of CpG-ODN, CCS of  315; 1 μg of CpG-ODN, CCS of 
349; 50 μg non-CpG-ODN, CCS of 360; 10 μg of non-CpG-ODN, CCS of 431; 1 μg of 
non-CpG-ODN, CCS of 454; or saline, CCS of 503). More birds in all groups other than 
the group treated with 50 μg CpG-ODN developed airsacculitis, pericarditis and 
perihepatitis,     either     alone    or     in     combination     (polyserositis).     Birds     that  
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 Fig. 3.1. Survival of neonatal chickens following treatment with different doses of 
CpG-ODN. Groups were treated intramuscularly with 50 (∆), 10 (○), or 1(◊) μg of CpG-
ODN, 50 (●), 10 (▲), or 1(▼) μg of non-CpG-ODN or saline (■). All birds were 
challenged subcutaneously with 1x107 cfu of Salmonella Typhimurium three days post 
treatment. Birds that received 50 μg of CpG-ODN showed significantly higher survival 
rates than groups treated with saline, 10 or 1 μg of non-CpG-ODN (p < 0.01). Birds 
treated with 10 or 1 μg of CpG-ODN were not protected against Salmonella 
Typhimurium infection. (p > 0.05) (n = 20). 
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Fig. 3.2. Cumulative  clinical  scores (CCSs) for  neonatal  chickens  following  treatment  
with different  doses of  CpG-ODN. The cumulative  clinical  scores  of individual  birds 
following subcutaneous challenge  with 1x107 cfu of  Salmonella Typhimurium three 
days post treatment with 50 (∆), 10 (○), 1 (◊) μg  of  CpG-ODN, 50 (●), 10 (▲), 1 (▼) 
μg  of   non-CpG-ODN or saline (■) are shown in this graph. Birds intramuscularly 
injected with 50 μg of CpG-ODN had the lowest CCS among groups (Bar = median) (n = 
20). 
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Table 3.1. Level of Salmonella Typhimurium isolated from the air sacs of neonatal 
                  chickens treated with different doses of CpG-ODN 
 
 
Salmonella 
Typhimurium 
challenge 
dose 
 
Salmonella 
Typhimurium 
growth 
(Score A) 
 
 
 
 
 
saline 
 
non- 
CpG- 
ODN 
50 μg 
 
 
CpG- 
ODN 
50 μg 
 
non- 
CpG- 
ODN 
10 μg 
 
 
CpG- 
ODN 
10 μg 
 
non- 
CpG- 
ODN 
1 μg 
 
 
 
CpG- 
ODN 
1 μg 
 
 
1x10 7 
cfu / bird 
 
0 
+1 
+2 
+3 
+4 
  
   1 B 
12 
3 
3 
1 
 
6 
6 
3 
3 
2 
 
6 
12 
1 
1 
0 
 
5 
7 
5 
2 
1 
 
2 
12 
4 
2 
0 
 
3 
6 
7 
4 
0 
 
5 
6 
7 
2 
0 
 
             
 
In the groups that were intramuscularly treated with different doses of CpG-ODN at day one of 
age and subcutaneously inoculated with 1x107 cfu of Salmonella Typhimurium three days 
later, bacteria were isolated as frequently from the air sacs at necropsy regardless of 
treatment (p = 0.28). 
A Salmonella Typhimurium growth on the TSIA plates were scored as follows: 0 = no 
growth; +1 = growth of bacteria on area 1; +2 = growth of the bacteria on area 1 and 2; 
+3 growth of bacteria on area 1, 2, and 3; +4 = growth of bacteria on area 1, 2, 3, and 4 
(n = 20). 
B  Number of birds. 
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died per acutely  within 24 hours of challenge did not have gross lesions but did have 
bacteria in the air sacs,  as  determined  by culture  (Table 3.1).  In groups treated with 
50 μg of CpG-ODN, bacteria were isolated less frequently from the air sacs than in 
groups  treated  with  10 and 1 μg  of  CpG-ODN,  all  non-CpG-ODN  groups  or saline; 
however the bacteria isolation scores were not significantly different (p = 0.28) (Table 
3.1).   
 
(b) Duration of CpG-ODN protection against Salmonella Typhimurium 
infection in neonatal broiler chickens  
Birds were treated with CpG-ODN at different times prior to challenge to 
determine the duration of the protective effect. Groups of birds that received CpG-ODN 
on days 1, 2, 3, 5, 7 and 9 prior to challenge had significantly better survival than the 
control group (p< 0.01) (Fig. 3.3). However, treatment with CpG-ODN one to two days 
prior to challenge with Salmonella Typhimurium induced the highest protection in 
neonatal chickens. The group that received CpG-ODN at the time of challenge was not 
significantly protected (p = 0.09). Patterns in clinical signs and bacterial isolations were 
similar to those in previous experiments. 
 
         (c) Effect of CpG-ODN on Salmonella Typhimurium septicemia  
To evaluate the protective effect of CpG-ODN against systemic infection, the 
level of bacteremia was monitored following challenge. Salmonella Typhimurium was  
isolated from birds in the control group, which received saline, at a higher levels 
(cfu/100 μl)  than  the group that received CpG-ODN  (P<0.001)  (Table 3.2). Moreover, 
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Fig. 3.3. Duration of protection induced by CpG-ODN against Salmonella Typhimurium 
infection. Percent survival of chickens following a single intramuscular administration 
of 50 μg of CpG-ODN at the age of 1, 2, 3  4, 6, 8, or 9 days followed by Salmonella 
Typhimurium challenge (1.1x108 cfu) at day nine of age. Groups of birds challenged 
subcutaneously with Salmonella Typhimurium at days 1, 3, 5, 6, 7 or 8 post-CpG-ODN-
treatment were significantly protected (p < 0.01). However, the highest protection 
occurred in groups that received CpG-ODN one to three days prior to the challenge (p > 
0.05) (n = 20). 
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Table 3.2. Salmonella Typhimurium isolated from blood of the birds treated with either 
                  saline or CpG-ODN 
                   
Time of blood collection 
/ hour 
Saline group 
(cfu) 
CpG-ODN (50 μg) group 
(cfu / ml) 
 
 
1 
3.0x102 
2.0x103 
2.5x105 
0 
0 
0 
 
6 
2.0x103 
3.5x105 
1.5x105 
0 
0 
0 
 
12 
5.5x107 
2.0x104 
2.0x104 
0 
0 
0 
 
18 
3.0x104 
2.5x106 
0 
0 
0 
0 
 
24 
4.5x106 
1.5x105 
4.5x107 
2.0x103 
2.0x103 
0 
 
48 
8.5x107 
5.5x107 
2.0x105 
1.0x103 
1.0x102 
0 
 
72 
4.0x106 
4.5x108 
7.0x106 
1.0x104 
1.0x104 
0 
 
96 
5.5x108 
4.5x108 
2.0x106 
2.0x104 
3.0x104 
0 
 
120 
7.5x106 
2.0x103 
2.5x105 
1.0x102 
0 
0 
 
144 
1.5x104 
0 
0 
0 
0 
0 
 
168 
0 
0 
0 
0 
0 
0 
 
 
One ml of blood was collected from the suboccipital cavernous sinus of three 
anesthetized birds at each time. The number of bacteria in blood samples was determined 
by plating ten-fold serial dilutions in duplicate on TSIA agar followed by incubation at 
37οC for 24 hours (n = 3).  
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the relative risk of having bacteria in the blood was lower in birds treated with CpG-
ODN than in birds treated with saline. Treatment also delayed the detection of bacteria 
in the control group. All birds with bacteria were positive at one hour post-challenge in 
the  control  group. In  contrast,  birds  treated  with  CpG-ODN did  not have  detectable  
bacteremia until 24 hours post-challenge. No bacteria were isolated from birds treated 
with CpG-ODN on days six and seven post-challenge, while birds were found positive 
in the control group (Table 3.2). 
 
 
      (d) Effect of in ovo administration of CpG-ODN at day 18 of incubation and 
            challenge with Salmonella Typhimurium at hatch   
A dose of 50 μg of CpG-ODN was effective in protecting neonatal chickens 
against Salmonella Typhimurium infection when delivered intramuscularly. A similar 
trial was conducted to evaluate the effect of in ovo delivery of CpG-ODN on day 18 of 
incubation against Salmonella Typhimurium. Birds given CpG-ODN by the in ovo route 
had significantly greater survival (p < 0.01) than birds in control groups that received 
non-CpG-ODN or saline (Fig. 3.4). Non-CpG-ODN treatment did not protect birds 
against death following Salmonella Typhimurium challenge (p > 0.05) and was similar 
to that of saline. There was a significant difference among CCS of groups given 
treatment in ovo (p = 0.02). Comparison of mean ranks of CCS by group showed that 
two sets of groups differed significantly (p < 0.05) (Fig. 3.5). Only the group treated  in 
ovo with  50 μg  of   CpG-ODN  (CCS  of  95)  did  not  belong  to  the  set  of   
unprotected groups, which had higher CCS (50 μg of non-CpG-ODN in ovo, CCS of 
157; or saline in ovo, CCS of 306). Birds treated with CpG-ODN had a lower number  of      
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Fig. 3.4.  Survival of neonatal chickens following in ovo treatment with CpG-ODN 
against Salmonella Typhimurium infection. Survival of chickens following in ovo 
treatment with 50 μg of CpG-ODN (◊), 50 μg non-CpG-ODN (▲), or saline (■) into the 
amniotic cavity of the eggs at day 18 of incubation. All birds were challenged 
subcutaneously with 1.1x106 cfu of Salmonella Typhimurium at day two of age. Birds 
that received CpG-ODN showed significantly higher protection against Salmonella 
Typhimurium than birds that received non-CpG-ODN or saline (p < 0.01). Birds that 
received 50 μg of non-CpG-ODN were not protected against Salmonella Typhimurium 
infection (p > 0.05) (n = 20). 
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Fig. 3.5. Cumulative clinical scores (CCSs) of neonatal chickens following in ovo 
treatment with CpG-ODN prior to inoculation with Salmonella Typhimurium. Eggs 
received 50 μg of CpG-ODN (∆), 50 μg of non-CpG-ODN (●), or saline (■) on day 18 
of incubation. All groups were challenged with 1.1x106 cfu of Salmonella Typhimurium 
at day two of age. The median CCS of birds treated with 50 μg was lower than that of 
other groups (Bar = median) (n = 20).  
 
 
 
 
 
 
 95
 
 96
Table 3.3. Level of Salmonella Typhimurium isolated from air sacs of neonatal 
                 chickens following in ovo treatment with CpG-ODN 
 
Salmonella 
Typhimurium 
challenge dose 
Salmonella 
Typhimurium 
growth (score *) 
 
 
saline A 
non- 
CpG-ODN 
50 μg AB 
 
CpG-ODN 
50 μg B 
 
1.1x106 
cfu 
0 
+1 
+2 
+3 
+4 
   4 ■ 
8 
4 
2 
2 
7 
7 
2 
2 
2 
13 
3 
2 
2 
0 
 
 
A  B Groups with different superscripts are significantly different (p<0.05). 
Birds treated with CpG-ODN had a lower number of bacteria isolated from air sacs 
compared to birds treated with saline. 
 * Salmonella Typhimurium growth on the TSIA plates was scored as follows: 0 = no 
growth; +1 = growth of bacteria on area 1;  +2 = growth of the bacteria on areas 1 and 2; 
+3 = growth of bacteria on areas 1, 2, and 3;  +4 = growth of bacteria on areas 1, 2, 3, 
and 4 (n = 20).                                                                                                                                               
■ Number of birds. 
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bacteria isolated from air sacs compared to birds treated with saline (Table 3.3) (p < 
0.05). 
 
   3.5. Discussion 
Synthetic CpG-ODN are known to be effective stimulators of the immune 
system and potent adjuvants in a number of species, including mice, primates and 
humans (Davis et al. 2000; Weeratna et al. 2000). Previously, CpG-ODN have been 
shown   to  protect  neonatal   and  mature  chickens  against  E. coli,  a   bacterium  with  
extracellular survival (Gomis et al. 2004). In the present study, this finding has been 
extended to include the effect of CpG-ODN against Salmonella Typhimurium, a 
bacterium with an intracellular phase of survival.  
The innate immune system is highly developed and has been well conserved 
over the course of evolution for rapid recognition and response to pathogens through 
recognition of PAMPs. One example of such recognition of PAMPs is that the 
vertebrate innate immune system (found in fish, birds and mammals) can discriminate 
bDNA from self-DNA by recognition of unmethylated CpG motifs present in the 
pathogen's DNA (Krieg 2002). CpG-ODN are therefore recognized as danger signal by 
the host and evoke innate immune responses, which in turn promote the host’s adaptive 
immune system to combat potential infections. It has been demonstrated here that CpG-
ODN are able to protect neonatal chickens against lethal infection with Salmonella 
Typhimurium. Protection by CpG-ODN was associated with lower clinical signs and 
decreased number of Salmonella Typhimurium in the blood. In previous studies, it was 
demonstrated that CpG-ODN stimulated a murine hepatocyte cell line to inhibit 
intracellular growth of Salmonella Typhimurium (Sanchez-Campillo et al. 2004) and 
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Salmonella Enteritidis infection in chickens (He et al. 2005b). Furthermore, a recent 
study suggested that chemokines and cytokines play a key role in the protective response  
against salmonellosis. Clearance of primary infection of Salmonella Typhimurium in the 
chicken appeared to involve IFN-γ-mediated TC responses (Withanage et al. 2005). 
These responses indicate that clearance of the systemic infection is primarily Th 1 
mediated (Carter 1990). 
Treatment with CpG-ODN provided effective protection when given one to three 
days prior to infection in an E. coli model, and appeared to have some effect for almost 
six days (Gomis et al. 2003). The duration of this effect represents a significant 
proportion of the neonatal lifespan of a broiler chicken, which commonly becomes 
infected with E. coli or Salmonella species. These infections result in a significant 
mortality and production loss for the poultry industry (Barnes 2003). Thus, injection of 
CpG-ODN in ovo to the developing embryo would be a feasible method to control these 
infections in the poultry industry. Currently, antibiotics are used in neonatal chickens as 
a preventative measure against bacterial infections. There is a potential to use CpG-
ODN given by the in ovo route to reduce the incidence of bacterial infection in neonatal 
poultry and replace the use of antibiotics. In ovo delivery of CpG-ODN at day 18 of 
incubation significantly protected neonatal birds against Salmonella Typhimurium 
infection. This protection is associated with minimizing bacteremia (Table 3.3). Birds 
treated with CpG-ODN showed delayed onset of septicemia and faster recovery from 
infection than birds in the control group (Table 3.2). The mechanism of bacterial 
clearance remains to be determined but likely is associated with IFN-γ and IL-18 (Patel 
et al. 2007). 
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 It is generally accepted that disease prevention by prophylactic measures or by 
immune stimulation is preferable to the use of therapeutic agents in the food animal 
industry. This has become especially important due to a number of food safety and 
human  health  issues.  Therefore,  the animal  production  industry  is  seeking  ways  of 
 reducing the use of antibiotics such as vaccination, strict bio-security and immune 
stimulation. Therefore, novel immunostimulants may serve as alternative, desirable 
ways to prevent disease.  
In conclusion, CpG-ODN were effective in protecting chickens against 
Salmonella Typhimurium infection. A large-scale field study is necessary to determine 
the commercial utility of CpG-ODN in preventing bacterial infections in neonatal birds. 
Future studies may develop the potential of CpG-ODN as stimulant of the innate 
immune system against infections in neonatal birds and an alternative to routine use of 
antibiotics in the poultry industry.   
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4.0. ENHANCEMENT OF IMMUNOPROTECTIVE EFFECT OF CPG-ODN BY  
       FORMULATION WITH POLYPHOSPHAZENES AGAINST E. COLI  
       SEPTICEMIA IN NEONATAL CHICKENS 
    4.1. Abstract 
 Synthetic oligodeoxynucleotides (ODN) containing CpG motifs (CpG-ODN) 
have been shown to be effective immunoprotective agents and vaccine adjuvants against 
a variety of bacterial, viral and protozoan diseases in different animal species. The 
objective of this study was to investigate the immunoprotective effect of CpG-ODN 
formulated with polyphosphazenes, liposomes or an oil-in-water emulsion against E. 
coli infections in neonatal chickens in separated trials. Eighteen-day-old embryonated 
eggs were inoculated with 50μg non-CpG-ODN, 50μg CpG-ODN or CpG-ODN 
formulated with polyphophazenes, liposomes or an Emulsigen®. Four days after 
exposure to CpG-ODN, non-CpG-ODN or formulated CpG-ODN, at one day post-
hatch, approximately 1x104 or 1x105 cfu of a virulent isolate of E. coli was inoculated 
subcutaneously into the neck. Clinical signs, pathology, bacterial isolations from the air 
sacs, and mortality were observed for eight days following challenge with E. coli. The 
survival rate of birds in groups receiving either non-CpG-ODN or saline following E. 
coli  infection  was  0%. In  contrast,    birds   given   either   CpG-ODN   or  CpG-ODN 
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 formulated with polyphosphazene had a significantly higher survival rate of 55% 
(P<0.0001). The relative risk of mortality was lower for birds treated with CpG-ODN 
formulated in PCPP (poly [di (sodium carboxylatophenoxy) phosphazene]) (0.25), CpG-
ODN formulated in PCEP (poly [di (sodium carboxylatoethylphenoxy) phosphazene]) 
(0.33), or unformulated CpG-ODN (0.39) in comparison to the group treated with saline  
(p<0.01). Although formulation of CpG-ODN with liposomes or an oil-in-water 
emulsion did not increase the immunoprotective effect against E. coli infection, no 
adverse reactions such as decreased hatchability or increased mortality were observed in 
embryos. This is the first time that CpG-ODN formulated with polyphosphazene has 
been demonstrated to have an immunoprotective effect against an extracellular bacterial 
infection in neonatal broiler chickens following in ovo delivery.  
 
 
   4.2. Introduction 
The innate immune system of vertebrates recognizes a specific molecular 
structure presented in pathogens that are known as PAMPs. Following recognition of 
PAMPs, the host immune system immediately responses to infection (Medzhitov and 
Janeway 2002). Recently, it has been found that bDNA is among PAMPs that can 
stimulate the innate immune system of different vertebrate species and afford immune 
protection against a variety of bacterial, viral, and protozoan  infections (Ashkar and 
Rosenthal 2002; Krieg 2002; Mutwiri et al. 2003). Bacterial DNA contains relatively 
abundant unmethylated CpG dinucleotides, while vDNA is methylated (Bird 1993). 
CpG motifs are now known to contribute to the immunostimulatory activity of bDNA 
(Ahmad-Nejad et al. 2002) and retain immunostimulatory activities (Yamamoto et al. 
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1992). CpG-ODN has direct stimulatory effects on monocytes and macrophages, which 
secrete IL-12 and other cytokines (Stacey et al. 2000). It activates NK cells to increase 
lytic activity and to secrete IFN-γ (Ballas et al. 1996). CpG-ODN have no apparent 
direct stimulatory effect on TCs, but they enhance the ability of APCs to active TCs 
(Krieg 1999). These effects have been seen in a variety of viral, bacterial and protozoan 
infections, among a range of vertebrate species, including poultry (Vleugels et al. 2002; 
Gomis et al. 2003; He et al. 2005a). 
Over the past decades, considerable efforts were devoted to the development of 
new experimental adjuvant formulations that would increase the immunogenicity of 
subunit and protein vaccines (Gupta et al. 1993; Aguado et al. 1999). Adjuvants are 
formulated compounds or additives that, when combined with Ags, help to direct or 
boost the body’s immune system (Gupta 1998). They are classified into two broad 
categories: I- delivery systems including particulate adjuvants such as liposomes and 
emulsions (Singh and O'Hagan 2002), and II- immunostimulatory adjuvants such as 
CpG-ODN (Davis et al. 1998). 
Polyphosphazenes are potent immunostimulatory adjuvants with a high 
molecular weight, containing a long-chain backbone of alternating phosphorus and 
nitrogen atoms (Lu 1996a; Andrianov 1998). Among polyphosphazenes, PCPP is a 
potent immunostimulant via not only  parenteral, but also mucosal vaccine delivery,  
against diseases such as influenza, tetanus toxoid, hepatitis B surface Ag, and herpes 
simplex virus (Payne et al. 1995). The adjuvant activity of a new polyphosphazene 
electrolyte (PCEP) as a potent enhancer of Ag-specific immune responses was recently 
studied  in  mice  inoculated   with  influenza  virus  (Mutwiri  et al.  2007).  This   study 
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 revealed that the adjuvant activity of PCEP is higher than that of PCPP, as PCEP 
induces higher levels of Th 1, Th 2 type cytokines, and IgG 1, IgG 2 associated with 
production of both IFN- γ and IL-4.  
 In this study, the efficacy of combining CpG-ODN with liposomes was 
investigated. Liposomes are produced from natural non-toxic phospholipids and 
cholesterol. The adjuvant effect of liposomes is mostly due to: I- depot formation at the 
injection site, II- selective uptake of liposomal Ags into regional lymph nodes and,  III- 
Ag presentation resulting from Ag clustering and massive delivery to APCs (Gregoriadis 
1990) (Cox and Coulter 1997). It has been demonstrated that encapsulating CpG-ODN 
into liposomes improves the incorporation of CpG-ODN into DCs, enhances IL-12, 
activates NK cells, and produces IFN-γ (Verma et al. 2004).  
Biphasic lipid vesicles of VTAs are composed of  I- an outer membrane with two 
layers of vesicle-forming lipids, II- a core compartment containing an oil-in-water 
emulsion, and  III- a dose of immunogen effective to elicit an immune response 
(Foldvari 1998). To improve the bioavailability and to optimize the immunostimulatory 
activity of CpG-ODN, Foldvari et al. (1998) developed a novel lipid-based delivery 
system, BiphasixTM VTA, suitable for administering vaccine Ags and CpG-ODN 
(Foldvari 1998). This delivery approach provided extended release and optimum 
exposure of the Ag and CpG-ODN to cells of the immune system. There is evidence that 
encapsulation of CpG-ODN in a delivery system can potentiate the adjuvant effects 
VTA (Mui et al. 2001; Alcon et al. 2003; Babiuk et al. 2004).  
Furthermore, it has been demonstrated that stabilized CLs (cationic lipids) 
improve      the      uptake     and       immunostimulatory      activity       of      CpG-ODN    
(Li  et al. 2001; Mui  et al. 2001). Liposomes stimulate both humoral and cell-mediated 
immunity, including CTL responses (Joseph et al. 2006; Yoshinaga et al. 2007). In an 
immunization model, encapsulation of CpG-ODN with the liposomal adjuvant CL 
increased IFN-  and IgG responses by 15- to 40-fold compared with CpG-ODN alone 
(Gursel et al. 2001).  These findings provide support that stabilized CLs enhance the 
therapeutic efficacy of CpG-ODN (Gursel et al. 2001).   
Emulsigen® is commonly used in veterinary vaccines. This adjuvant acts by 
forming a depot of Ag, which can target immune effectors cells such as, IFN-γ, Th 1, 
and IgG (Linghua et al. 2006; Lopez et al. 2006). The depot effect, which results in slow 
release of Emulsigen® improves the presentation of Ags, thereby enhancing the immune 
response (Zaloga et al. 2007). Emulsigen® is a unique oil-in-water adjuvant, without 
components of animal origin (Zaloga et al. 2007).  
Previously, we have demonstrated that unformulated CpG-ODN delivered in ovo 
were potent immunostimulants against bacterial infections in neonatal chickens. The 
objective of this study was to investigate if the immunoprotective effect of CpG-ODN in 
neonatal chickens could be enhanced by formulating CpG-ODN with polyphosphazenes, 
liposomes or Emulsigen®. 
 
   4.3. Materials and methods 
      4.3.1. E. coli culture and animal model  
A field isolate of E. coli obtained from a turkey with septicemia was used as the 
challenge strain. This E. coli isolate was from serogroup O2, which is non-hemolytic, 
serum resistant, and produced aerobactin and has a K1 capsule and type one pili 
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(Ngeleka et al. 1996). Aliquots of bacteria were stored at 70○C in 50% BHI (Difco, 
Detroit, MI) supplement with 25% (v/w) glycerol (VWR Scientific, Inc., Montreal, 
Quebec). Bacteria for use as the challenge were cultured on BHI agar for 18-24 hours at 
37○C. Two to three colonies were added to 200 ml of Luria Broth (LB) (Miller-BDH 
Inc.) in a one-L Erlenmeyer flask. The culture was grown at 37○C for 18-20 hours with 
shaking at 200 rpm. The stationary phase culture was diluted to an optical density of 0.4 
at 600 nm. At this concentration, the culture contained approximately 2.5 x 108 colony-
forming units (cfu) of bacteria. The cultures were further diluted in BHI to the 
concentration of bacteria required to challenge birds. The E. coli challenge dose was 
confirmed by plating serial dilutions of the diluted culture in duplicate on BHI plates, 
followed by incubating for 18 hours at 37○C, and counting the number of colonies.              
All procedures involving animals were done according to a protocol approved by the 
University of Saskatchewan, Committee on Animal Care. CpG-ODN was administered 
to eggs after 18 days of incubation, as described previously for the E. coli model 
developed in neonatal broilers by Gomis  et al. (Gomis et al. 2004). Hatching eggs were 
obtained from a local hatchery in Saskatchewan, Canada. Eggs were hatched at  the  
Poultry  Hatchery,  Department  of  Animal  and  Poultry  Science,  University of 
Saskatchewan. At the time of hatch birds were identified with individual neck tags 
(Swiftack Poultry Tags, Heartland Animal Health Inc., MO). Groups of 20 chickens 
were randomly assigned and placed in separate rooms at the Animal Care Unit, Western 
College of Veterinary Medicine, University of Saskatchewan. Water and commercial 
broiler ration were provided ad libitum. Each room had non-recirculated air. 
Photoperiods of 24 hours per day for the first three days and 16 hours per day for the 
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remaining seven days were established. Room temperature was maintained at 30-32 ○C 
for the first week and 28-30○C for the second week. Birds were challenged 
subcutaneously into the neck with 1x104 or 1x105 cfu of E. coli at day one post hatch or 
day four-post administration of formulated CpG-ODN.  
Birds were observed for clinical signs for eight days following challenge with E. 
coli. Daily clinical scores for individual birds were assigned as follows: 0 = normal; 1 = 
hesitant to move and easily fatigued; 2 = euthanized; 3 = dead. Cumulative clinical 
scores (CCSs) for each bird (CCS/Bird) and for each group of 20 (CCS/Group) were 
calculated as follows:  
CCS/Bird- Clinical scores were summed for each bird across the eight days of 
the trial. Birds that had been euthanized were given a score of 2 for the day of 
euthanasia and 3 for each day remaining in the trial. Dead birds were given a score of 3 
for each day remaining in the trial, including the day of death.  
CCS/Group- Clinical scores for each bird were summed across groups of 20 
birds to give a CCS for each group.  
Dead  or  euthanized  birds  were necropsied  immediately. Gross  lesions such as  
pericarditis, perihepatitis, airsacculitis and polyserositis were recorded.  Bacterial swabs 
were taken from the air sacs and cultured on MacConkey agar plates (Becton, Dickinson 
and Company Sparks, MD). Growth of E. coli on the plates was recorded as follows: 0 = 
no growth; +1 = growth of bacteria on area 1; +2 = growth of the bacteria on areas 1 and 
2; +3 = growth of bacteria on areas 1, 2 and 3; and +4 = growth of bacteria on areas 1, 2, 
3 & 4 (Barry 1972). 
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      4.3.2. Synthetic CpG-ODN  
The sequence of CpG-ODN used was TCGTCGTTGTCGTTTTGTCGTT (2007) 
and the sequence of non-CpG-ODN was TGCTGCTTGTGCTTTTGTGCTT (2007). Both 
ODNs were free of endotoxin (provided by Qiagen-GmbH, Hilden Germany) and were 
produced with a phosphorothioate backbone. Synthetic CpG-ODN was diluted in sterile, 
pyrogen free saline. 
 
      4.3.3. Preparation of Polyphosphazenes 
Polyphosphazene polyelectrolytes PCPP and PCEP were designed and 
synthesized by Parallel Solutions Inc. (Cambridge, MA) using previously described 
procedures (Mutwiri et al. 2007). Aqueous solutions of both polymers were stored at 
room temperature in the dark. Batches of polyphosphazenes found to have endotoxin 
levels below 0.034 ng/ml, as assessed by Limulus Amebocyte Lysate assay 
(Biowhittaker, Walkersville, MD). Fifty μg of CpG-ODN was formulated with 50 μg of 
polyphosphazenes to obtain a total volume of 100 μl of PBS.  
 
 
      4.3.4. Preparation of biphasic lipid vesicles, vaccine targeting adjuvant (VTA)  
            and cationic lipid (CL)  
BiphasixTM Vaccine Targeting Adjuvant (VTA) (Formulation codes: VTA-4 and 
VTA-6), a lipid-based delivery system and cationic lipids (CL-16 and CL-18) were 
developed at PharmaDerm Laboratories Ltd. Saskatoon, Saskatchewan, Canada. VTA 
was prepared as described previously (Foldvari 1998; Foldvari et al. 1999; Gursel et al. 
2001). Briefly, the lipid  phase components  were mixed  together at  70°C and  hydrated 
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 with the microemulsion aqueous phase. The resulting biphasic vesicles (a multi-
compartmental system consisting of aqueous, micellar, amphipathic bilayer, and 
hydrophobic compartments) were mixed with 50 μg CpG-ODN solution at 9:1 (v/v).  
 
      4.3.5.  Preparation of Emulsigen® 
Emulsigen® is a common adjuvant in poultry vaccines (Johnston et al. 1997). In 
this study, Emulsigen® was used to formulate CpG-ODN for delivery by the in ovo 
route. This adjuvant was obtained from MVP Laboratories Inc., Ralston, NE. On day 18 
of incubation, eggs were inoculated with either: I- 90 μl of 30% Emulsigen® together 
with 50 μg CpG-ODN in 10 μl of saline,  II- 90 μl of 10% Emulsigen® together with 
CpG-ODN 50 μg in 10 μl of saline, or  III- 90 μl of  30% Emulsigen® in 10 μl of saline. 
 
 
   4.4. Experimental design: 
      (a) Formulation   of   CpG-ODN   with  polyphosphazenes  for  in ovo protection 
           against E. coli infection in neonatal chickens   
 
In ovo administration is known to be a safe, efficacious and convenient method 
for vaccinating poultry (Ricks et al. 1999). Thirteen groups of 25 embryonated eggs 
were randomly allocated to treatments. The groups were injected on day 18 of 
incubation with CpG-ODN, non-CpG-ODN, PCPP, PCEP, PCPP together with CpG-
ODN, PCEP together with CpG-ODN, or saline. All groups of 20 birds were challenged 
with either 1.5x104 or 1.5x105 cfu of E. coli at day one post-hatch and kept separately in 
different rings (four days after in ovo treatments). Clinical scores were recorded and 
bacteria isolated as described above.  
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To determine if formulation of CpG-ODN with polyphosphazenes enhanced the 
duration of protection against E. coli, additional groups of birds were inoculated with the 
above formulations by the in ovo route. These birds were challenged with 1x104 cfu of 
E. coli at day-four post-hatch (seven days after in ovo treatment). Clinical scores were 
recorded and bacteria isolated as described above.  
 
 
(b) Formulation  of CpG-ODN  with  VTA  for  in ovo protection  against   
      E. coli infection in neonatal chickens 
Embryonated eggs were randomly allocated to six groups of 25. On day 18 of 
incubation, groups were injected with CpG-ODN, VTA-4, VTA-6, VTA-4 together with 
CpG-ODN, VTA-6 together with CpG-ODN, or saline. On day one post-hatch, all 
groups of 20 birds were challenged with 2x104 or 2x105 cfu of E. coli (four days after in 
ovo treatment) and kept in different rings. Clinical scores were recorded and bacteria 
isolated as described above. 
 
(c) Formulation of CpG-ODN with cationic lipids for in ovo protection against  
      E. coli infection in neonatal chickens     
Embryonated eggs were randomly allocated into six groups of 25. On day 18 of 
incubation, groups were injected with CpG-ODN, CL-14, CL-16, CL-14 together with 
CpG-ODN, CL-16 together with CpG-ODN, or saline. All groups containing 20 birds 
each were challenged with 2x104 or 2x105 cfu of E. coli on day one post-hatch (four 
days   after    in ovo  treatment)   and   kept   in   different   rings.  Clinical   scores   were  
recorded and bacteria isolated as described above. 
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      (d) Formulation of CpG–ODN with Emulsigen® for in ovo protection against 
            E. coli infection in neonatal chickens  
Embryonated eggs were randomly allocated into five groups of 25. On day 18 of 
incubation, groups were inoculated with CpG ODN, 10% Emulsigen®, 10% 
Emulsigen® together with CpG-ODN, 30% Emulsigen® together with CpG-ODN, or 
saline. All birds were challenged with 1.5x104 or 1.5x105 cfu of E. coli on day one post-
hatch (four days after in ovo treatment) and kept in separate groups. Clinical scores were 
recorded and bacteria isolated as described above. 
 
   4.5. Statistical analysis 
The survival pattern and median survival were compared using the log-rank test. 
Survival data was analyzed using Prism (Prism 4.0, GraphPad Software Inc., San Diego, 
CA. USA www.graphpad.com)  with  p = 0.05. The  effect  of treatments on relative risk  
of mortality and on cumulative clinical scores was analyzed using proportional hazards 
regression and Kruskal-Wallis non-parametric analysis of variance with comparison of 
mean ranks using Statistic (Analytic Software, Tallahassee, FL USA, 
www.statistix.com). Chi-square tests in Statistic were used to test the homogeneity of 
the relative frequency distribution of the level of bacteria in air sacs after treatments. 
 
   4.6. Results  
      (a) Formulation of CpG-ODN with polyphosphazenes for in ovo protection  
           against E. coli infection in neonatal chickens   
The relative risk of mortality was significantly lower in birds treated with CpG-
ODN formulated in PCPP (0.25), CpG-ODN formulated in PCEP (0.33), or 
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unformulated CpG-ODN (0.39) in comparison to the group treated with saline (p < 0.01) 
(Fig. 4.1).  The PCEP treatment without CpG-ODN also provided a modest degree of 
protection compared to the saline treatment (relative risk of mortality = 0.57, p < 0.05). 
The immunoprotective effect and mortality rates were similar in groups challenged with 
1.5x104 and 1.5x105 cfu of E. coli, so data were pooled for groups given the two 
challenge doses.  The estimated risk of dying was 0.68 times lower in birds treated with  
CpG-ODN formulated in PCPP than in birds treated with unformulated CpG-ODN (p = 
0.04).  The proportion of birds treated with CpG-ODN formulated in PCEP that died  
was lower than those treated with unformulated CpG-ODN; however the difference not 
significant (p = 0.35).  
  Groups that received CpG-ODN together with PCPP had the lowest cumulative 
clinical  score  (354),  followed  by  birds  that received  CpG-ODN  together with 
PCEP(449),  CpG-ODN (501),  PCEP (601),  or saline (777),  PCPP (758),  or non-CpG 
(804) (Fig. 4.2).  
Overall, the effect of treatment group on CCS was highly significant (p < 0.001). 
Groups with significantly different mean ranks are shown in Fig. 4.2.  The majority of 
birds in groups not protected against E. coli infection developed airsacculitis, 
pericarditis and perihepatitis, either alone or in combination  (polyserositis) compared to 
birds in groups treated with CpG-ODN formulated with polyphosphazene or CpG-ODN 
alone. Birds that died per acutely within 24 hours of challenge did not have gross 
lesions, but bacteria were cultured from the air sacs (Table 4.1). In groups treated with 
CpG-ODN formulated with polyphosphazene or CpG-ODN alone, fewer bacteria were 
isolated from the air sacs compared to other groups (Table 4.1). (χ2 = 51.02; p < 0.001 ). 
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 Fig. 4.1. Survival of neonatal chickens following in ovo administration of CpG-ODN 
formulated with polyphosophazenes. Chickens were subcutaneously challenged with 
1.5x104 and 1.5x105 cfu of E. coli in groups treated in ovo with CpG-ODN (○), non-
CpG-ODN (●), PCPP (▼), PCEP (▲), CpG-ODN together with PCPP (□) CpG-ODN 
together with PCEP (∆) or saline (■). Birds that received CpG-ODN or CpG-ODN 
formulated with PCPP or PCEP showed a significantly higher survival rate (p < 0.01) 
compared to groups that received non-CpG-ODN or saline. The immunoprotective 
effect and mortality rates were similar in groups challenged with 1x104 and 1x105 cfu of 
E. coli, so data were pooled for groups given the two challenge (n = 40 for each 
treatment). 
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Although the highest immunoprotection was seen in the group treated with CpG-ODN 
formulated with PCPP, there was no significant difference in cumulative clinical score 
or bacterial isolation between groups treated with CpG-ODN alone and CpG-ODN 
formulated with PCPP (p > 0.05).  
 In  order to determine  if the  formulation of  CpG-ODN  with  polyphosphazenes 
enhances the duration of protection against E. coli challenge, additional groups of birds 
were challenged with 1x104 cfu of E. coli at day four-post hatch (seven days after in ovo 
treatment).  None  of  the  groups  treated  with  CpG-ODN  formulated  with 
polyphosphazenes or CpG-ODN alone showed protection of this duration against E. coli 
mortality, compared to the control group treated with saline (p > 0.05). 
 
 
        (b) Formulation  of  CpG–ODN  with  VTA for in ovo protection against E.  
      coli infection in neonatal chickens 
Survival of birds treated with CpG-ODN was significantly  greater  than survival 
of birds in groups treated with VTA-4, VTA-6 or saline (p < 0.01). Groups treated with 
CpG-ODN formulated either with VTA-4 or VTA-6 did not show higher 
immunoprotection   against  E. coli  infection  than  the  group  treated  with  CpG-ODN 
alone(p > 0.05) (Fig. 4.3). There were no significant differences in cumulative clinical 
score or bacterial isolation between groups treated with CpG-ODN alone and CpG-ODN 
formulated with VTA-4 or VTA-6 (p > 0.05).  
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Fig. 4.2. Cumulative clinical scores (CCSs) in birds following in ovo treatment with 
CpG-ODN formulated in PCPP and PCEP. Cumulative clinical score of individual birds 
following challenge with 1.5x104 and 1.5x105 cfu of E. coli via subcutaneous route in 
groups treated with saline, CpG-ODN (○), non-CpG-ODN (●), PCPP (▼), PCEP (▲), 
CpG-ODN  together with PCPP (□) CpG-ODN together with PCEP (∆) or saline (■). 
Birds that received CpG-ODN formulated with PCPP had lowest CCS among groups. 
Groups with different letters above the cluster of symbols are significantly different (p < 
0.05) (Bar = median). The immunoprotective effects were similar in groups challenged 
with 1x104 and 1x105 cfu of E. coli, so data were pooled for groups given the two 
challenge (n = 40 for each treatment). 
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Table 4.1. Level of E. coli isolated from air sacs of neonatal chickens following in ovo 
                 treatment with CpG-ODN formulated with PCPP and PCEP 
 
E. coli 
Growth 
(scores *) 
 
 
Saline AB 
   non- 
  CpG- 
ODN ABC 
 
  CpG- 
ODN BCD 
 
 
PCPP A 
 
 
PCEP ABC 
PCPP+ 
CpG- 
ODN D 
PCEP+ 
CpG- 
ODN CD 
 
0 
+1 
+2 
+3 
+4 
 
   0 ■ 
4 
12 
12 
12 
 
0 
11 
17 
12 
0 
 
7 
8 
9 
10 
6 
 
0 
1 
13 
18 
8 
 
 
5 
4 
14 
10 
7 
 
19 
4 
8 
3 
6 
 
7 
11 
7 
10 
5 
 
 
Groups with different superscript letters designations are significantly different (p < 
0.05). Embryonated eggs incubated for 18 days received different formulations as shown 
above. Overall, these in ovo treatments had a significant effect on bacterial load in air 
sacs (p < 0.001). The immunoprotective effects were similar in groups challenged with 
1x104 and 1x105 cfu of E. coli, so data were pooled for groups given the two challenge 
(n = 40 for each treatment). 
* E. coli growth on the MacConkey plates were scored as follows: 0 = no growth; +1 = 
growth of bacteria on areas 1; +2 = growth of the bacteria on areas 1 and 2; +3 = growth 
of bacteria on areas 1, 2, and 3; +4 = growth of bacteria on areas 1, 2, 3, and 4. 
■  Number of birds. 
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(c) Formulation of CpG-ODN with cationic lipids for in ovo protection against 
      E. coli infection in neonatal chickens     
Survival of birds treated with CpG-ODN was significantly greater than survival 
in groups treated with CL-14, CL-16 or saline (p < 0.01). Groups treated with CpG-
ODN formulated either with CL-14 or CL-16 did not have a greater immunoprotection 
against E. coli infection compared to the group treated with CpG-ODN alone (p > 0.05) 
(Fig. 4.4). There were no significant differences in cumulative clinical score or bacterial 
isolation between groups treated with CpG-ODN alone and CpG-ODN formulated with 
CL (p > 0.05).  
 
(d)  Formulation of CpG–ODN with Emulsigen® for in ovo protection against 
      E. coli infection in neonatal chickens    
Survival  of birds  treated with  CpG-ODN  was  significantly greater than that of groups 
treated with 10% oil-in-water Emulsion® or saline (p< 0.01). CpG-ODN formulated 
either with 10% oil-in-water Emulsion® or 30% oil-in-water Emulsion® did not  
produce an  enhanced  immunoprotective  effect  against E. coli infection (p > 0.05), 
compared to the group treated with CpG-ODN alone (Fig. 4.5). There were no 
significant differences in cumulative clinical score or bacterial isolation between  groups 
treated with CpG-ODN alone and CpG-ODN formulated with Emulsion® (p > 0.05).  
 
 
   4.7. Discussion 
Synthetic oligodeoxynucleotides containing CpG motifs act as immunostimulants 
and are capable of accelerating and boosting innate and adaptive immunity. CpG-ODN  
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Fig. 4.3. Survival of neonatal chickens following in ovo treatment of CpG-ODN 
formulated with VTA. Chickens were subcutaneously challenged with 2x105 cfu of E. 
coli and treated with CpG-ODN (○), VTA-6 (▼), VTA-4 (▲), CpG-ODN together with 
VTA-6 (□), CpG-ODN together with VTA-4 (∆) or saline (■). Birds that received CpG-
ODN or CpG-ODN formulated with VTA-6 or VTA-4 showed significantly higher 
survival rates (p < 0.01) compared to groups that received saline (n = 20). 
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Fig. 4.4. Survival of neonatal chickens following in ovo treatment of CpG-ODN 
formulated with CL. Chickens were subcutaneously challenged with 2x104 cfu of E. coli 
and treated with CpG-ODN (○), CL-18 (▼), CL-16 (▲), CpG-ODN together with CL-
18 (□), GpG-ODN together with CL-16 (∆) or saline (■). Birds that received CpG-ODN 
or CpG-ODN formulated with Cl-18 or CL-16 showed significantly higher survival rates 
(p < 0.01) compared to groups that received saline (n = 20). 
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Fig. 4.5. Survival of neonatal chickens following in ovo treatment of CpG-ODN 
formulated with Emulsigen®. Groups of chickens were subcutaneously challenged with 
1.5x105 cfu of E. coli and treated with CpG-ODN (○), Emulsigen® 30% (▲), CpG-
ODN together with Emulsigen® 30% (∆), CpG-ODN together with Emulsigen® 10% 
(□) or saline (■). There were no significant differences among groups treated with CpG-
ODN together with Emulsigen® 10%  and Emulsigen® 30% and the saline group [Em = 
Emulsigen®] (n = 20). 
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induces maturation and activation of vertebrate immune cells, which then produce Th 1-
type cytokines including TNF-α, IL-12, and IFN-γ. Therefore, CpG-ODN activation 
contributes to the development of Th 1-type immune responses (Yamamoto 2002; 
Klinman 2003). The immunoprotective effect of CpG-ODN against E. coli septicemia in 
chickens has been demonstrated previously (Gomis et al. 2003; He et al. 2005b). 
However, the effect of formulating CpG-ODN with other adjuvants to enhance activity 
against bacterial diseases in poultry has not been described. This study demonstrates that 
formulating CpG-ODN with polyphosphazenes synergizes the effectiveness of CpG-
ODN in providing protection against E. coli septicemia in neonatal chickens.  
Formulating CpG-ODN with appropriate adjuvant constitutes a way to potentate 
the effects of these immunostimulatory molecules. This effect is likely due to protection  
of CpG-ODN from degradation while increasing the uptake of CpG-ODN by cells of the 
immune system (Singh and O'Hagan 2002). The present investigation demonstrates that 
the polyphosphazenes PCPP and PCEP can enhance CpG-ODN-induced innate 
immunity  and  protection  against   bacterial  infections  in  neonatal   chickens.  It  may   
be  possible to enhance immune  stimulation of  CpG-ODN  by  optimizing  the  ratio  of  
CpG-ODN to PCPP or PCEP. Further studies are required to investigate this possibility. 
Innate immunity against different infectious agents requires distinct types of immune 
responses. Although CpG-ODN formulated with polyphosphazenes increase 
immunoprotective activity against E. coli septicemia in neonatal chickens, this 
combination did not lengthen the duration of protection. We have previously 
demonstrated that in ovo delivery of CpG-ODN without formulation had an 
immunoprotective effect against E. coli infection for a period of six days (Gomis et al. 
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2003). This period of protection was not lengthened by adding polyphospazene 
formulation of CpG-ODN (data not shown).   
It has been described previously that CpG-ODN are effective mucosal adjuvants 
and that VTA formulations are suitable delivery systems for CpG-ODN by the intra-
nasal route (Foss and Murtaugh 1999; McCluskie et al. 2000; Gallichan et al. 2001). On 
the other hand, CLs have been used to successfully deliver antisense oligonucleotides to 
inhibit protein expression in target tumor cells (Zhang et al. 2001) and anti-HIV therapy 
(Duzgunes et al. 2001) by facilitating cytoplasmic delivery and protecting against 
nuclease digestion. Combining CpG-ODN with CLs provides long in vivo stability that 
may enhance cytokine secretion (IL-12, IFN-γ and IL-6) and interaction with APCs 
(Gursel    et al.    2001;   Sellins    et al.    2005).    We    did    not    see    synergism   of 
immunostimulatory activity of CpG-ODN formulated with VTA, CLs or Emulsigen® in 
our experiments or even an additive effect. It has been well documented  that the CpG-
ODN-lipid complex can potentially create a depot effect at the site of inoculation, from 
which CpG-ODN are slowly released and presented to the immune system over a 
prolonged  period. (Foldvari  et al. 1999). It  is  possible  that  our formulations  were not  
optimized for the amniotic environment and the lipid vesicles containing CpG-ODN, 
and VTA or CL did not facilitate uptake and transport to the APCs of the mucosal 
immune systems of the respiratory and intestinal tracts of the developing embryo. 
However, the mechanism by which VTA or CL formulations of CpG-ODN act in the 
amniotic cavity is not known and needs further studies. Although our formulations of 
CpG-ODN with liposomes and Emulsigen® did not increase the immunoprotective 
effect,  we  did  not  see any  reduced  hatchability of chicken  embryos because of  these  
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formulations.  
In conclusion,  CpG-ODN  formulated with  polyphosphazenes  and delivered by 
the in ovo route to eggs at day 18 of incubation resulted in an increased 
immunoprotective effect against E. coli infections in neonatal chickens. Protection of 
neonatal chickens against E. coli infection by administration of CpG-ODN is likely 
mediated by IFN-γ and IL-18 mediated pathways (Patel et al. 2007). In addition, we 
have demonstrated that in ovo administration of CpG-ODN to incubating eggs is a safe 
and feasible method of delivery. There are clear advantages to using in ovo delivery 
methods. Historically, many immunizations in the poultry industry were subcutaneous 
injections administered to day-old chickens. Those techniques have now been replaced 
with  in ovo technology,  which  is  considered  less  invasive. Further work is needed  to  
understand the mechanisms by which CpG-ODN and polyphosphazenes formulations 
enhance the immunoprotective activity of CpG-ODN in the amniotic cavity of chicken 
embryos. 
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5.0. GENERAL SUMMARY AND DISCUSSION 
 The chicken mucosal immune system does not fully mature until weeks after 
hatch. Indeed, the enteric immune system is very poorly developed in newly hatched 
chickens (Barrow et al. 1987). Therefore, chickens under three days of age, which 
experience severe systemic diseases, experience high morbidity and mortality. Among 
those diseases that target newly hatched chicks, salmonellosis due to Salmonella 
Typhimurium and colibacillosis due to E. coli are the most economically important 
(Barnes 2003; Withanage et al. 2005). Many efforts have been made to reduce mortality 
due to Salmonella Typhimurium and E. coli septicemias in neonatal chickens, but with 
limited success. Control measures which are recommended to reduce the economic loss 
includes strict biosecurity, probiotics, and antibiotic therapy. However, these measures 
also increase the production cost. Moreover, the use of antibiotics in reducing mortality 
of neonatal chickens increases the possibility of the emergence of antibiotic resistant 
strains of bacteria. Recently, poultry companies have started raising chickens without 
antibiotics. To achieve this goal, they must increasingly depend on vaccines (Souza 
2007). This also increases production expenses. These increased costs are passed on to 
the consumer. Therefore, the poultry industry is looking for alternative approaches for 
controlling  mortality in neonatal  chickens  that would simultaneously reduce the use of  
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antibiotics and production cost. Recently, immunostimulants have been considered as 
possible alternatives to minimize losses due to bacterial infection in newly hatched 
chicks. 
 Immune systems containing cells, chemokines, cytokines, and immunoglobulins 
play a key role in the protective responses against diseases such as, salmonellosis and 
colibacillosis in poultry (Kariyawasam et al. 2002; Withanage et al. 2005). Clearance of 
primary infection by Salmonella Typhimurium in the chicken appears to involve mostly 
IL-1-β, IL-6, and IFN-γ mediated TC (primarily Th 1) responses (He et al. 2003; 
Withanage et al. 2005). E. coli induce a Th 1 like response with abundant IFN-γ, IgG, 
IgA, IgM, and IL-12, but little or no IL-4, IL-13, and IL-5 and activate macrophages and 
heterophils, which play a key role in fighting E. coli infections in chickens 
(Kariyawasam et al. 2002; Mellata et al. 2003). Therefore, using innate immune 
stimulators that promote rapid responses to microbial pathogens in neonatal chickens is 
of great interest to the poultry industry. 
 For nearly a century it has been known that bDNA extracts have 
immunostimulatory and therapeutic effects (Morales 1978; Tokunaga et al. 1992). 
Bacterial DNA extracts activate NK cells and produce type 1 and type 2 interferons 
(Tokunaga et al. 1992; Yamamoto et al. 1992). Unmethylated CpG motifs in bDNA 
trigger protective pathways similar to those activated by PRRs and detect endotoxins 
and other microbial products (Krieg 2002). In addition, they are responsible for 
stimulation of lymphocyte proliferation and variable effects on immunoglobulin 
production   in   oligodeoxynucleotides   with  a   PS   backbone  (Bird  1993).   Immune 
recognition of CpG motifs are shown to increase production of BCs, NK cells, and  DCs  
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(Krieg 2002). Due to the strength and nature of this stimulation, CpG-ODN has been 
investigated for immune therapeutic and protective use in a variety of animal species 
(Krieg 2002). 
It has been demonstrated that CpG-ODN has an immunoprotective effect against 
E. coli that often infects neonatal broiler chickens (Gomis et al. 2004). However, studies 
on the effect of CpG-ODN against Salmonella in neonatal chickens were limited to in 
vitro studies of CpG-ODN against Salmonella Enteritidis (He et al. 2005b). In order to 
study the in vivo affect of CpG-ODN against Salmonella Typhimurium, an intracellular 
bacterium, we first developed an animal model in neonatal broiler chickens using avian 
and mammalian isolates of Salmonella Typhimurium. Both human and chicken isolates 
produced salmonellosis with high mortality and similar pathologic lesions of 
pericarditis, perihepatitis, airsacculitis, and polyserositis in neonatal chickens because 
the two isolates shared the same virulent factor genes (15 out of 15). In contrast, the 
house sparrow isolate failed to induce mortality in neonatal chickens, possibly due to the 
lack of two of 15 virulent factor genes present in the other isolates (personal 
communication-Allan, B.).  
Stationary phase Salmonella Typhimurium was chosen as our challenge at a dose 
of 1x106 and 1x107 cfu. This challenge produced clinical disease and mortality at a level 
that was sufficient for our future experiments. We also demonstrated that clinical 
salmonellosis and pathological lesions in this animal model were not associated with the 
LPS of Salmonella Typhimurium, but rather with live Salmonella Typhimurium 
septicemia.  
Administration of  50 μg  of  CpG-ODN  intramuscularly (leg), one to three days  
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prior to challenge with Salmonella Typhimurium increased the protection against 
septicemia. This protection was shown to last for at least six days. Birds treated with 
CpG-ODN had lower bacterial loads of Salmonella Typhimurium and fewer associated 
pathologic lesions and clinical signs when compared to birds treated with saline. By day 
six of age, CpG-ODN completely cleared Salmonella Typhimurium from peripheral 
blood of treated chicks. Recently, it has been demonstrated that systemic clearance of 
Salmonella Typhimurium is partially associated with cellular responses such as 
secretion of IFN-γ mediated TCs in chickens (Withanage et al. 2005). Therefore, it can 
be implied that the immune stimulatory effect of CpG-ODN against Salmonella 
Typhimurium is primarily Th 1 type mediated. 
Over the past two decades, the rapidly growing poultry industry has accepted in 
ovo injection to control Marek’s disease and administer antibiotics as preventive 
measures (Johnston et al. 1997). A number of immune and antibody responses can be 
induced in embryos at 12-14 days of incubation, soon after the emergence of T and B 
lymphocyte cell progenitors (Houssaint et al. 1991; Cormier 1993). The in ovo method 
provides early accelerated immune response that may improve protection against poultry 
diseases (Gagic et al. 1999). Recently, it was demonstrated that in ovo delivery of CpG-
ODN protected neonatal broiler chickens against E. coli septicemia (Gomis et al. 2004). 
The present investigation demonstrated that in ovo delivery of CpG-ODN at day 18 of 
incubation protected neonatal chickens against Salmonella Typhimurium infection. It is 
hoped that in ovo delivery of 50 μg of CpG-ODN could protect neonatal chickens 
against E. coli and Salmonella Typhimurium septicemia under field conditions. This 
would be very advantageous to the poultry industry.  
 
 127
During the last decade, the efficacy of combining CpG-ODN with adjuvants to 
enhance the immunoprotective effect of vaccines has been investigated. Our research is 
the first to demonstrate that CpG-ODN formulated with polyphosphazenes such as 
PCPP and PCEP enhances innate immunity against bacterial infections in neonatal 
chickens. However, further studies are required to investigate the mechanisms by which 
CpG-ODN formulated with PCPP or PCEP enhance immune protection against E. coli 
septicemia. While CpG-ODN formulated with PCPP or PCEP enhanced immune 
protection against E. coli septicemia, the duration of protection was not increased. On 
the other hand, there was no significant difference between the survival rates of birds 
that received CpG-ODN formulated with polyphosphazene groups and groups treated 
with CpG-ODN alone (p = 0.35). It is possible that the ratio of CpG-ODN to PCPP or 
PCEP used in this experiment was not optimal.  Further research is required to 
determine the optimal ratio. 
In our study, the respective effects of in ovo delivery of CpG-ODN formulated in 
liposomic adjuvants such as VTA and CLs, and CpG-ODN formulated with 
Emulsigen® were also investigated. VTA  has been shown previously to improve the 
adjuvant activity of CpG-ODN following intranasal delivery (Babiuk et al. 2004) or 
systemic administration in pigs (Alcon et al. 2003). CLs are known to facilitate 
cytoplasmic delivery of CpG-ODN, as they protect CpG-ODN from nuclease digestion 
and potentiate activation of innate immunity (Briane et al. 2002; Rocha et al. 2002). 
Therefore, the incorporation of CpG-ODN with liposomes provides longer in vivo 
stability that may result in enhanced cytokine secretion (IL-12, IFN-γ and IL-6) (Lu 
1996b).  Emulsigen®, which  has  been  known  to have longer deposition at  the  site of 
 128
 immunization, is used in inactivated bacterial or viral vaccines with the potential to 
elicit higher levels of antibodies (Foldvari 1998). In each of our experiments, in ovo 
delivery of formulated CpG-ODN with VTA, CL and Emulsigen® did not enhance 
protection against E. coli infection compared to CpG-ODN alone. It is likely that these 
adjuvants cannot improve the adjuvant activity of CpG-ODN following in ovo delivery 
and our formulations may not have been optimized for the environment in the amniotic 
cavity where chicken embryos were developing. However, we did not observe poor 
hatchability of chicken embryos using these formulations suggesting that they are safe in 
ovo. 
 In summary, CpG-ODN was a significant immunoprotective agent against 
Salmonella Typhimurium infection in neonatal broiler chickens. Intramuscular injection 
at day one of age or in ovo delivery of 50 µg of CpG-ODN at day 18 of incubation 
significantly increased the survival rate (p < 0.01) when compared to the control 
treatments groups. We have also demonstrated that in ovo delivery of 50 µg of CpG-
ODN formulated with polyphosphazenes such as PCPP and PCEP is a safe method for 
increasing the immunoprotective effect against E. coli infections of neonatal chickens. 
These findings provide a foundation for the development of immune stimulants for the 
protection against bacterial infections that have the potential to replace or supplement 
antibiotic therapy. 
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